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ABSTRACT

An abstract of the dissertation of Vidya Dhote for the Doctor of Philosophy in
Chemistry presented February 12, 2009.

Title: Characterization of Putative Self-Resistance Genes in the Biosynthetic Gene
Cluster of Hygromycin A from Streptomyces hygroscopicus NRRL 2388

Streptomyces hygroscopicus NRRL 2388 produces an aminocyclitol antibiotic
called hygromycin A (HA), which targets bacterial protein synthesis by inhibiting the
peptidyl transferase reaction. The hyg6, hygl9, hyg21, hyg28, and hyg29 genes in the
biosynthetic gene cluster of HA are predicted to confer self-resistance to the producer
strain by different mechanisms. Targeted gene disruptions and in vitro characterization
of recombinant proteins were carried out to elucidate the functions of these genes. The
hygll gene encodes an O-phosphotransferase with a proposed role in HA inactivation
by phosphorylation. Disruption of hygll led to a significant decrease in HA
production but did not affect self-resistance. The recombinant Hyg21 phosphorylated
HA and its analogs bearing a conserved fucofuranose moiety, using ATP or GTP as
phosphoryl donor. The phosphorylated HA was inactive against HA-sensitive E. coli
and Streptomyces strains, and also lacked the ability to inhibit in vitro protein
synthesis.
The hyg6 and hyg29 genes are methyltransferase homologs and are predicted
to confer resistance by ribosomal RNA methylation. Disruption of hyg6 resulted in the

production of desmethylenehygromycin A and 5"-dihydrodesmethylenehygromycin
A, which lacked the C4-C5 methylenedioxy bridge characteristic of HA.
Desmethylenehygromycin A had higher protein synthesis inhibition activity than HA
but significantly lesser antibiotic activity. Disruption of hyg29 did not affect selfresistance but the antibiotic yield was reduced.
The hygl9 and hyg28 genes putatively encode a proton gradient-dependent
transporter and an ATP-binding cassette transporter, respectively, and are
hypothesized to confer resistance by antibiotic efflux. A Ahyg28 mutant resembled the
wild type in antibiotic production and self-resistance levels. A Ahygl9 mutant
produced lesser amounts of HA and also showed accumulation of 5"dihydrohygromycin A, but there was no decrease in resistance. Disrupting hygl9
together with hygll significantly increased HA sensitivity, indicating that HA selfresistance in the producer strain arises by synergistic functioning of multiple gene
products. Accumulation of 5"-dihydrohygromycin A in Ahygl9 also suggested that
this compound is the immediate biosynthetic precursor of HA and that its
dehydrogenation is coupled with efficient HA efflux. A short chain dehydrogenase
encoded by hyg26 was shown to reversibly catalyze the above reaction using NAD(H)
as cofactor.
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1. Introduction
1.1 General introduction to Streptomyces and secondary metabolic pathways
The Streptomyces genus, within the bacterial order Actinomycetales, is
comprised of Gram-positive, filamentous, soil bacteria with a characteristically high
G+C content (> 60%) in their genome [1]. These bacteria show complex
morphological differentiation in their life cycle, similar to filamentous fungi, and
therefore, are regarded as 'boundary organisms' between prokaryotes and eukaryotes
[2]. The streptomycete life cycle begins with the germination of spores to form
filamentous, branched, aseptate structures called hyphae. The hyphae spread out
extensively on solid medium and form the substrate mycelium. Subsequently, some
hyphae grow away from the substrate to form the aerial mycelium. When growth in
the aerial mycelium ceases, they develop septa and form unigenomic compartments
that mature into spores. The appearance of aerial mycelium coincides with the
activation of secondary metabolic pathways (pathways that are not directly involved in
the normal growth and development of an organism), which synthesize a large number
of structurally diverse compounds. The function of these 'natural products' in the
bacteria producing them is to serve as defense molecules, or as signals for cellular
differentiation or cell-cell communication, thereby conferring ecological advantages to
the producer species in their environmental niches [3]. The importance of these
compounds to humans lies in the fact that they also possess interesting
pharmacological properties and have found clinical applications as antibiotics (eg.
erythromycin, tetracycline), antifungal compounds (eg. amphotericin B, nystatin),
1

anticancer agents (eg. doxorubicin, chromomycin), cholesterol-lowering drugs (eg.
lovastatin, pravastatin), immunosuppressants (eg. rapamycin, FK506), livestock
growth promoters (eg. monensin, tylosin), and insecticides (eg. spinosad) (FIGURE
1).
Erythromycin A

2

The genes encoding the biosynthesis of a given secondary metabolite are
typically clustered within the genome of the producing organism, and may have
evolved by duplication of existing primary metabolic genes [4, 5]. Biosynthesis of the
secondary metabolites proceeds from precursors that are intermediates or products of
primary metabolism, and the enzymes involved show significant structural and
functional similarities to primary metabolic enzymes. This is exemplified by the
polyketide synthases (PKS) from which the largest class of secondary metabolites,
namely the polyketides, is derived. Polyketide biosynthesis occurs in a manner
analogous to fatty acid biosynthesis, and a component of the PKS can be functionally
complemented, to some extent, by its counterpart in the fatty acid synthase (FAS)
system [6-8]. Fatty acid synthases synthesize long-chain saturated fatty acids from
acetyl-CoA and malonyl-CoA through a series of iterative decarboxylative
condensation, ketoreduction, dehydration, and enoyl reduction steps. The FAS system
is comprised of either a single multi-domain polypeptide carrying out several catalytic
functions (Type I FAS) as in vertebrates, or a set of monofunctional proteins (Type II
FAS) as in bacteria and higher plants. Similar to FASs, type I PKSs comprised of
multimodular proteins, and type II PKSs comprised of multiple dissociable enzymes
are present (FIGURE 2) [9]. A third type of PKS, type III, also exists, which is
composed of iteratively-acting dimeric enzymes but is independent of the noncatalytic acyl carrier protein (ACP) component.
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FIGURE 2. Organization of type I, type II, and type III polyketide synthases
ACP - Acyl carrier protein, AT - Acyltransferase, KS - Ketosynthase, KR - Ketoreductase,
DH - Dehydratase, ER - Enoylreductase, TE - Thioesterase. Figure adapted from [9].

Structural diversity of the polyketides arises because the PKSs can utilize a wide range
of acyl groups as starter and extender units. Moreover, the P-keto group may be
reduced to different extents during chain elongation. The polyketide backbone also
undergoes several modifications such as oxidation, methylation, and glycosylation
(post-PKS tailoring steps), which give rise to further structural variations [10, 11].

Extensive genetic engineering of the secondary metabolite biosynthetic gene
clusters has facilitated the production of several new compounds, thereby increasing
the chemical diversity of available natural products [12, 13]. It is thought that the
secondary metabolites isolated from Streptomyces so far represent only a small
fraction of the total number of compounds that members of this genus are capable of
producing [14]. Analysis of the completed Streptomyces genome sequences has
revealed the existence of several additional gene clusters that synthesize compounds
other than those already known [15-18]. Presently, there is an urgent need for new
antibiotics because of the rapid onset of resistance that has rendered several
antibacterials ineffective [19-21]. The Streptomyces species, being such prolific
producers of natural products, can continue to be a rich source for the discovery and
development of novel antibiotics and other bioactive compounds of therapeutic
relevance.

1.2 Hygromycin A
Hygromycin A (HA, compound 1) is a secondary metabolite produced by
Streptomyces hygroscopicus NRRL 2388 (FIGURE 3). HA was initially isolated in
5

1953 and was shown to have moderate antibiotic activity against several Grampositive and Gram-negative bacteria [22]. Several other interesting biological
activities have been discovered for this compound. HA and an analog,
methoxyhygromycin A (compound 3, FIGURE 3) produced by the same strain, have
been reported to inhibit the K88 fimbrial protein-mediated erythrocyte agglutination
ability of enterotoxic E. coli [23]. HA has been found to be effective in controlling
dysentery in pigs caused by Serpulina hyodysenteriae [24, 25]. Immunosuppressant
properties have also been demonstrated for HA [26]. HA and 3 can also act as plant
growth inhibitors / herbicides, and have been proposed as possible candidates for
development into weed control agents [27, 28].

1.2.1 Antibacterial action of HA
Structurally, HA belongs to the aminocyclitol class of antibiotics that are
characterized by the presence of a cyclohexane moiety with hydroxyl and amino or
guanidino substituents. Some examples of this class of compounds are streptomycin,
spectinomycin, gentamicin, and kanamycin. These antibiotics inhibit protein synthesis
by binding to the 30S ribosomal subunit and preventing its interaction with mRNA
[29]. The antibacterial activity of HA, however, is brought about by a different
mechanism involving inhibition of the peptidyl transferase center within the 50S
ribosomal subunit [30]. The presence of HA prevents the binding of chloramphenicol
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FIGURE 3. Structures of hygromycin A and related compounds. The three
structural moieties in HA, 5-dehydro-a-L-fucofuranose (A subunit), (£)-3-(3,4dihydroxyphenyl)-2-methylacrylic acid (B subunit), and 2L-2-amino-2-deoxy-4,5-0methylene-neo-inositol (C subunit), are indicated. HA, 3, and 5 also exist in small
amounts as their corresponding C4" epimeric forms, which appear as 'shoulder peaks'
with slightly earlier retention times in all HPLC traces.

or lincomycin, two other known peptidyl transferase inhibitors, suggesting that these
antibiotics have overlapping binding sites or bind in close proximity to one another.
HA binds more strongly to ribosomes than chloramphenicol, and hence is a more
potent protein synthesis inhibitor. HA binding is precluded only by the 50S-targeting
macrolides tylosin, carbomycin, and spiramycin that incorporate a disaccharide moiety
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in their structure [31]. Thus, the structural features and binding mode of HA
distinguish it from other ribosome-targeting antibiotics, offering possibilities for the
development of new analogs to combat drug-resistant bacteria.

1.2.2 Structure and biosynthesis of HA
HA has a molar mass of 511, is highly soluble in water, and has an absorption
maximum at 272 nm [23, 32]. Its structure is comprised of three very dissimilar
moieties, namely 5-dehydro-a-L-fucofuranose, (£)-3-(3,4-dihydroxyphenyl)-2methylacrylic acid, and the aminocyclitol 2L-2-amino-2-deoxy-4,5-0-methylene-neoinositol, which will be referred to as the A, B, and C subunits, respectively (FIGURE
3). It is interesting to note that HA shows significant structural similarities to two other
antibiotics, A201A (compound 8) and puromycin (compound 9) (FIGURE 3). HA
resembles A201A in having similar A and B subunits, whereas with respect to
puromycin, the structure of the B subunit is conserved. Structure-activity relationship
studies showed that replacing the fucofuranose moiety in HA with a pyranose sugar
significantly reduced the antibacterial activity, whereas substituting it with an allyl
ether did not affect activity [33, 34]. An HA analog lacking the fucofuranose subunit
or an allyl ether analog without the aminocyclitol completely lacked bioactivity [34].
Replacing the hydroxyl on the central phenyl ring with an amine group retained
antibacterial activity, whereas substituting it with methyl or methoxy groups, or
introducing functional groups at other positions on the phenyl ring reduced activity
[34, 35]. Analogs with heteroaryl groups in place of the phenyl group were completely
inactive [35]. Reduction in activity was observed when the methyl group in the B
8

moiety was replaced with propyl, allyl, or hydrogen [34]. The presence of the C4-C5
methylenedioxy bridge of the aminocyclitol subunit has been reported to be essential
for optimal antibacterial activity of HA; compound 3, the naturally occurring analog of
HA with a methoxy group at C5, is significantly less active than HA [23, 36].
Introducing hydroxyl or methoxy groups at different positions on the aminocyclitol
decreased in vivo activity in varying degrees [37, 38].

Detailed isotope-labeled precursor feeding studies were carried out by the
Reynolds group to investigate the biosynthetic pathway of HA (FIGURE 4) [39].
Stable, isotopically labeled precursor compounds were fed to growing cultures of S.
hygroscopicus. Following fermentation, HA was isolated and examined by 13C NMR.
The feeding experiments showed that both D-[l,2-13C2]glucose and D-[l-13C]mannose
were incorporated into the A subunit, suggesting that biosynthesis of the A subunit
originates from glucose-6-phosphate, which is converted to fructose-6-phosphate and
then to mannose-1-phosphate. The subsequent steps in the proposed pathway involve
the generation of the nucleotide diphosphate (NDP)-activated mannose and conversion
to NDP-L-fucose via a NDP-4-keto-6-deoxymannose intermediate. The NDP-Lfucose then undergoes ring contraction to form L-fucofuranose and a subsequent
oxidation at C5 to form 5-dehydro-a-L-fucofuranose, or the A subunit.
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Figure taken from [40].
13,

Incorporation of [carboxy- C]-4-hydroxybenzoic acid and [2,313,

C2]propionate into the B subunit of HA suggested that this subunit is generated in a

polyketide synthase-like manner. The proposed biosynthetic route for this branch of
the pathway is initiated by the decarboxylative condensation of 4-hydroxybenzoylCoA starter unit with the propionate-derived methylmalonyl-CoA extender unit,
followed by reduction and dehydration steps. The C subunit is also derived from
glucose, but its biosynthesis is proposed to involve a myoinositol intermediate.
Oxidation of the C5 hydroxyl of rayo-inositol and its subsequent transamination yields
neo-inosamine-2, which makes the core aminocyclitol. The methylene group of the
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C4-C5 methylenedioxy bridge is derived from S-adenosylmethionine, as suggested by
feeding studies with L-[methyl-13C]-methionine. These individual subunits of HA get
linked to one another by a glycosidic bond between A and B, and an amide linkage
between B and C subunits.

The putative biosynthetic pathway was subsequently used by the Reynolds
group as a basis for developing a strategy to identify the biosynthetic gene cluster of
HA in S. hygroscopicus (GenBank DQ314862) (FIGURE 5) [40]. Degenerate primers
for a gene encoding a putative mannose dehydratase (MDH), which would convert
NDP-mannose to NDP-4-keto-6-deoxymannose during A subunit biosynthesis, were
used to amplify a MDH homolog from the S. hygroscopicus genome. This gene was
next used to screen a cosmid library to identify the HA biosynthetic gene cluster.
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FIGURE 5. Biosynthetic gene cluster of hygromycin A from S. hygroscopicus
NRRL 2388. The gene cluster is comprised of 29 open reading frames with predicted
roles in HA biosynthesis, resistance, and pathway regulation (see TABLE 1).

Functional annotation of the 31.5 kb gene cluster recognized 29 open reading frames
(ORFs), designated hygl-29, whose protein products have been assigned to most of
the reactions in the pathway (TABLE 1). Putative regulatory elements and resistance
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determinants have also been identified in the gene cluster. A gene disruption
experiment was carried out to confirm the function of the HA gene cluster [41].
Disruption of the hyg26 gene, which encodes a putative short chain dehydrogenase
proposed to convert L-fucofuranose to 5-dehydro-a-L-fucofuranose, resulted in the
production of the reduced analogs of HA and 3, namely 5"-dihydrohygromycin A
(compound 2) and 5"-dihydromethoxyhygromycin A (compound 4) (FIGURE 3). This
experiment confirmed that the gene cluster isolated was responsible for HA
biosynthesis.
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TABLE 1. Genes in the hygromycin A biosynthetic gene cluster
Gene

Proposed function

hygl

protein length
375

AfsR regulatory protein

hyg2

399

p-hydroxybenzoate hydroxylase

hyg3

323

Regulatory protein

hyg4

173

Chorismate lyase

hyg5

352

Mannose dehydratase

hyg6

249

Methyltransferase

hyg7

579

Unknown

hyg8

411

Aminotransferase

hyg9

83

Acyl carrier protein

hyglO

378

P-ketoacyl synthase 1

hygll

252

Unknown

hygl2

451

CoA ligase

hygl3

96

Acyl carrier protein

hygl4

347

3-hydroxyacyl ACP dehydratase

hygl5

256

3-ketoacyl ACP reductase

hygl 6

431

Glycosyltransferase

hygl 7

330

nryo-inositol dehydrogenase

hygl8

363

myoinositol-1 -phosphate synthase

hygl9

416

Transmembrane protein

hyg20

370

Transglucosylase

hygll

183

Phosphotransferase

hyg22

391

Acyltransferase

hyg23

325

Fucose synthase

hyg24

287

Unknown

hyg25

213

wryo-inositol-1 -phosphatase

hyg26

271

Short chain dehydrogenase

hyg27

401

DAHP synthase

hyg28

570

ATP binding cassette transporter

hyg29

378

Methyltransferase

1.3 Self-resistance mechanisms in antibiotic producers
S. hygroscopicus, like other bacteria that produce antibiotics, is equipped with
mechanisms to protect itself from the lethal effects of its own destructive molecules.
Generally, the genes responsible for self-resistance are found clustered with the
antibiotic biosynthesis genes and are thought to have co-evolved with the latter to
provide timely auto-immunity [42]. This appears to be the case for HA resistance
genes also. The three most commonly encountered methods of self-resistance include
1) antibiotic inactivation by enzymatic modification, 2) modification of the cellular
target for the antibiotic, and 3) exclusion of the antibiotic from the cell. Sequestration
of the antibiotic by specific binding proteins, and changes in cell wall permeability
also serve as additional means of self-protection in some strains. Many species use
more than one method of resistance simultaneously, which provides them with
multiple layers of protection.

1.3.1 Self-resistance by antibiotic modification
Resistance by enzymatic inactivation of antibiotic is primarily mediated by Ophosphorylation of hydroxyl groups and iV-acetylation of amino groups. In some
cases, resistance is also brought about by O-glycosylation or amino acid addition. The
donor groups for these modifications are ATP, acetyl-CoA, UDP-glucose, and Lleucine, respectively.
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1.3.1.1 ^-phosphorylation and N-acetylation
O-phosphorylation or 7V-acetylation as a means of antibiotic inactivation is
widely observed in producers of the protein synthesis-inhibiting aminoglycoside
antibiotics [42]. The ribosomes of these bacteria, which are the targets for the
antibiotics, are not modified, and so remain sensitive throughout the bacterial life
cycle. Covalent modification of the antibiotic by a functional group prevents or
weakens its binding to the target, thus conferring resistance to the producer. It is
frequently observed that the phosphotransferase and acetyltransferase activities
function in conjunction with each other for maximum resistance. For example, the
neomycin-producing S.fradiae possesses a 3'-<9-phosphotransferase and a 3-Nacetyltransferase, and the resistance of a S. lividans expression host strain equals that
of the producer only when the genes for both these enzymes are heterologously
expressed in it (FIGURE 6) [43]. Similar observations have been made in the
paromomycin-producer, S. rimosus [44]. Modification can occur not only on the final
product, but also on pathway intermediates/precursors during antibiotic biosynthesis.
This is best illustrated in streptomycin biosynthesis by S. griseus (FIGURE 6). The
strA gene in the streptomycin biosynthetic gene cluster encodes streptomycin-6phosphotransferase, which phosphorylates streptidine, an intermediate in the
biosynthetic pathway. The remaining biosynthetic steps take place on this
phosphorylated precursor, leading to the production of an inactive, phosphorylated
form of streptomycin, 6'-phosphorylstreptomycin [45, 46]. An extracellular
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B. Phosphorylation of streptomycin occurs on a pathway intermediate to form inactive 6'phosphoryl streptomycin, which gets dephosphorylated extracellularly.
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phosphatase dephosphorylates 6'-phosphorylstreptomycin to form the bioactive
streptomycin [47]. Similarly, in the puromycin-producing S. alboniger, the
puromycin-iV-acetyltransferase acts on 0-demethylpuromycin, a toxic intermediate in
the biosynthetic pathway, such that puromycin is synthesized in its inactive acetylated
form, which is deacetylated extracellularly [48].

1.3.1.2 0-glycosylation
Antibiotic inactivation by 0-glyosylation has been reported exclusively from
the macrolide-producing Streptomyces sp. and has been well-characterized in the
oleandomycin-producer, S. antibioticus. Macrolides including erythromycin,
oleandomycin, pikromycin, and tylosin bind to the 50S ribosomal subunit and cause a
premature termination of protein synthesis. The ribosomes of macrolide producers are
normally modified by methylation, and therefore are resistant to antibiotic action [42].
However, the ribosomes of S. antibioticus are susceptible to oleandomycin throughout
its life cycle [49]. Resistance to oleandomycin is conferred by synthesizing
oleandomycin in an inactive glycosylated form (FIGURE 7) [50]. A glycosyl
transferase encoded by the olel gene in the oleandomycin gene cluster catalyzes this
modification [51]. Glycosylated oleandomycin is exported out of the cell, where an
extracellular glycosidase encoded by the oleR gene of the oleandomycin gene cluster
deglycosylates it into active oleandomycin. A second glycosyltransferase, OleD, with
an ability to glycosylate a broad range of macrolides, has also been characterized from
S. antibioticus, but the gene encoding it is not a part of the oleandomycin gene cluster,
and so OleD is considered to have a more general role in resistance that is not coupled
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with antibiotic biosynthesis. A similar resistance mechanism involving glycosylation/
deglycosylation has also been observed in the biosynthesis of pikromycin by S.
venezuelae [52].

1 x Acetyl CoA
6 x Malonyl CoA

PKS
*"

Post PKS

Oleandomycin
Active

Oleandolide

O l e l ^ - - - UDP-glucose
Glucose

Glycosylated oleandomycin
Inactive
ATP-

ADP + Pi"
Intracellular

OleB

Extracellular

Glycosylated oleandomycin
Inactive
OleR

k

Glucose

Oleandomycin
Active

FIGURE 7. Antibiotic modification by glycosylation. Intracellular oleandomycin is
made inactive by glycosylation and reactivated extracellularly by a glycosidase.
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1.3.1.3 Modification by leucine addition
Antibiotic inactivation by addition of a leucine residue has been reported only
from S. griseochromogenes, which produces the peptidyl-nucleoside antibiotic
blasticidin S [53]. Modification with leucine occurs on a toxic biosynthetic
intermediate, demethylblasticidin S to form leucyldemethylblasticidin S, which has
reduced antibiotic activity. Methylation of leucyldemethylblasticidin S yields
leucylblasticidin S, which gets exported out of the cell and is hydrolyzed to form
blasticidin S.

1.3.2 Modification of antibiotic target site
A second mode of resistance seen in bacteria is modification or replacement of
the antibiotic target site. Depending on the target type, this can be classified as 1)
ribosomal, involving the ribosomal RNA (rRNA), and 2) non-ribosomal, involving
targets such as DNA gyrase, RNA polymerase, or elongation factor Tu.

1.3.2.1 Methylation of ribosomal RNA
Resistance in bacteria that possess ribosomes tolerant to ribosome-targeting
antibiotics is usually achieved by monomethylation or dimethylation of nucleotides on
ribosomal RNA, and is the major route for self-protection in macrolide producers.
Ribosomal methylation in an antibiotic producer was first studied in S. azureus, which
produces thiostrepton [54]. The tsr gene product in this organism is a constitutively
expressed 0-methyltransferase that modifies the 2'-hydroxyl of an adenosine in the
23S rRNA (FIGURE 8) [55]. Self-resistance in Saccharopolyspora erythraea to
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erythromycin is conferred by the ermE gene product, which is an adeninedimethylating JV-methyltransferase (FIGURE 9) [43]. In the tylosin producer, S.
fradiae, a 23S rRNA dimethylase encoded by tlrA, along with two monomethylases
encoded by tlrB and tlrD, provide resistance [56-58]. TlrA confers high levels of
resistance by dimethylating an adenine residue. TlrD monomethylates at the same
position as TlrA, while TlrB acts on a guanine residue. Experiments using a tylosinsensitive E. coli strain showed that neither TlrB nor TlrD confers any appreciable
levels of protection on its own, and that the two enzymes have to act synergistically
for maximum resistance [58, 59]. RNA methylation is also observed in some
aminoglycoside producers. An example is guanine monomethylation in the 16S rRNA
of the gentamicin producer S. tenebrarius [60]. RNA modification prevents critical
binding interactions between the drug and its target, which prevents or decreases drug
binding and results in resistance.

16S rRNA : A1408
kamB gene from apramycin
producer S. tenebrarius

16S rRNA: G1405
kgm gene from gentamycin
producer M. purpurea

23S rRNA: A1067
tsr gene from thiostrepton producer S. azureus

FIGURE 8. Ribosomal RNA modification. The different possible sites of
modification on ribosomal RNA nucleotide are shown.
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1.3.2.2 Replacement of non-ribosomal target sites
Self-resistance in some antibiotic producers is mediated by expression of
resistant forms of non-ribosomal targets. Three well-studied examples are 1) DNA
gyrase inhibition by aminocoumarins, 2) elongation factor Tu (EF-Tu) inhibition by
kirromycin, and 3) glyceraldehyde-3-phosphate dehydrogenase inhibition by
pentalenolactone.

DNA gyrase is a bacterial topoisomerase that catalyzes ATP-dependent
negative supercoiling of DNA. The enzyme is a heterotetramer comprised of two
GyrA subunits and two GyrB subunits [61]. GyrA is responsible for the double strand
breakage and re-ligation of DNA, whereas GyrB is responsible for ATP hydrolysis.
The aminocoumarin antibiotics novobiocin, clorobiocin, and coumermycin Al act by
inhibiting the ATPase activity of GyrB [62]. The producer strains for these antibiotics,
S. spheroides, S. roseochromogenes var. oscitans, and S. rishiriensis, respectively,
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make themselves self-resistant by producing an alternate, resistant form of GyrB
encoded by the gyrBR gene in the corresponding antibiotic biosynthetic gene cluster
[63-65]. Studies in the novobiocin producer revealed that the predominant GyrB,
termed GyrBs, was novobiocin-sensitive, whereas GyrBR was novobiocin-resistant. It
was observed that expression of gyrBR was induced by the antibiotic and that GyrBR
replaced GyrB from the gyrase tetramer once novobiocin production began [66-68].

S. arenae, the producer of pentalenolactone, also protects itself by synthesizing
alternate isoforms of glyceraldehye-3-phosphate dehydrogenase, the target for the
antibiotic [69]. Expression of the sensitive form of the enzyme is observed only in the
absence of pentalenolactone production and is replaced by the resistant form once
antibiotic production is initiated.

The kirromycin class of antibiotics inhibit protein synthesis by interacting with
elongation factor Tu and immobilizing it on the ribosome [70]. The Ef-Tu identified in
the kirrothricin producer, S. cinnamoneus, is intrinsically resistant to the antibiotic
[71]. An alternate, sensitive form of EF-Tu has not been identified in this strain.

1.3.3 Antibiotic efflux pumps
Efflux pumps are often found in antibiotic biosynthetic gene clusters. These
proteins are associated with the cell membrane and are involved in secretion of the
antibiotic from inside the cell. They also contribute to self-resistance because active
export prevents intracellular accumulation of the drug, thereby keeping the drug
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concentration at levels that are tolerable for the bacterium. One of the types of efflux
pumps found in antibiotic producers is the proton motive force pumps belonging to the
major facilitator superfamily. These transporters have either 12 or 14 transmembrane
segments and utilize a proton gradient across the membrane for transport [72, 73].
Proton gradient-dependent efflux pumps have been identified in the gene clusters of
puromycin and actinorhodin [74, 75]. A second category of efflux pumps is the ATP
binding cassette (ABC) transporters, which couple antibiotic export to ATP
hydrolysis. Structurally, they are comprised of two hydrophilic ATP-binding domains
and two hydrophobic transmembrane domains, which may be present on the same
protein or on different polypeptides [76]. The ABC transporters in antibioticproducing actinomycetes have been classified into three groups [77]. The Type I
transporter system comprises two genes, one of which encodes a protein with a single
ATP binding domain, and the second gene present immediately downstream encodes a
membrane protein with six transmembrane segments. Type I ABC transporters have
been identified in daunorubicin, tetronasin, mithramycin, and oleandomycin producers
[78-81]. The Type II group is comprised of a single gene that encodes a protein with
two ATP binding domains; a gene for the membrane component has not been
identified in the corresponding biosynthetic gene cluster. Transporters of this type
occur in carbomycin, tylosin, oleandomycin, A201A, and lincomycin producers [8286]. The type ITI system is made of a single gene that encodes a protein with one ATP
binding domain and one transmembrane domain. This type has been reported from the
bleomycin and streptomycin producers [87, 88].
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1.4 Antibiotic resistance in pathogens
Emergence of pathogenic bacteria with high levels of antibiotic resistance,
often to multiple drugs, is a serious problem that is affecting not only the treatment of
infectious diseases but also other medical areas where the risk of bacterial infection
exists, such as organ transplantation, surgery, and chemotherapy. Drug resistance has
now become a constant challenge for antibacterial drug development. One of the ways
by which bacteria become refractory to drugs is through the independent evolution of
point mutations in their genome, which creates resistance genes [89]. A second way,
considered more effective for the acquisition and dissemination of resistance, is
through the horizontal transfer of antibiotic resistance genes via gene cassettes,
transposons, plasmids, and bacteriophages from other taxonomically distant bacteria in
the environment, including antibiotic producing strains [90]. The resistance
mechanisms in a pathogenic bacterium against a given antibiotic often have identical
counterparts in the producer strain from which the antibiotic is derived. For example,
the aminoglycoside-inactivating kinases in clinical strains are similar to the antibioticmodifying kinases from the Streptomyces that produce these antibiotics [91].
Similarly, some glycopeptide- antibiotic producers harbor resistance genes that are
homologous to the vancomycin resistance genes in Enterococcus [92]. Therefore, it is
widely accepted that antibiotic resistance in pathogens has originated from the selfresistance mechanisms occurring in antibiotic producers [90, 93, 94]. However, the
antibiotic producers are, obviously, not the only contributors for clinical resistance,
especially for the semisynthetic and synthetic drugs. The general microbial population
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in the soil ('soil antibiotic resistome'), living in the presence of antibiotic producers
and also simultaneously exposed to man-made chemicals, forms a much larger
reservoir of resistance genes [95]. Laboratory studies of resistance in non-pathogenic
strains, including the producers, against a novel clinically relevant antibiotic can assist
in the elucidation of resistance mechanisms that can potentially develop once its
clinical use increases. Information gained from such studies can be used to develop
better antibiotic analogs and also for developing inhibitors that would target the
resistance mechanism itself.

1.5 Putative self-resistance mechanisms in S. hygroscopicus NRRL 2388

FIGURE 10. Putative self-resistance mechanisms in S. hygroscopicus NRRL 2388.
Analysis of the HA biosynthetic gene cluster identified four genes that are
likely to contribute to self-resistance of the producer strain, S. hygroscopicus NRRL
2388 [40]. The hyg21 gene shows similarity to (^-phosphotransferases and is predicted
to confer resistance by antibiotic inactivation. As HA is a ribosome-targeting
antibiotic, a possible route of self-resistance in S. hygroscopicus can be target site
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modification by rRNA methylation. A SAM-dependent methylation step is involved in
biosynthesis of the methylenedioxy bridge of HA's aminocyclitol moiety. Two
methyltransferase homologs, hyg6 and hyg29, have been recognized in the HA gene
cluster, and it is hypothesized that one of these encodes an O-methyltransferase for
methylenedioxy bridge formation and the other encodes an rRNA methyltransferase
for resistance. The hygl9 gene shows similarity to proton gradient-dependent
transporter genes. The hyg28 gene resembles ABC transporter genes and putatively
encodes a type II ABC transporter. It is proposed that Hygl9 and/or Hyg28 are
responsible for efflux of HA, thereby conferring self-resistance.

1.6 Specific aims of current research
The objective of the present research is to investigate the mechanisms of selfresistance in S. hygroscopicus NRRL 2388 by characterizing the putative resistance
determinants found in the biosynthetic gene cluster of HA. The specific aims are:

1) Characterize the hygll gene product and test its role in HA inactivation.

2) Determine if either hyg6 or hyg29 contributes to self-resistance by rRNA
methylation, and if the second gene encodes an 0-methyltransferase that introduces
the methyl group of the C4-C5 methylenedioxy bridge in HA.

3) Determine the roles of the two putative transporter systems encoded by hygl9 and
hyg28 in HA efflux-mediated resistance.

2. Antibiotic resistance: An ^-phosphotransferase catalyzes phosphorylation of
hygromycin A in the producing organism, Streptomyces hygroscopicus

2.1 Summary
The hyg21 gene in the hygromycin A (HA) biosynthetic gene cluster encodes
an (^-phosphotransferase with a proposed role in self-resistance of S. hygroscopicus. It
was observed that insertional inactivation of hyg21 leads to a greater than 90%
decrease in HA production. The wild type and the hyg21 mutant were comparably
resistant to HA. Using E. coli as a heterologous host, Hyg21 was expressed and
purified. Kinetic analyses revealed that the recombinant protein catalyzes
phosphorylation of HA (Km 29.2 + 4.4 |iM) at the C2" position of the fucofuranose
ring in the presence of ATP (Km 198.3 + 19.1 ^M) or GTP (Km 356.5 + 62.1 ^M) with
a kcat of 2 min"1. The phosphorylated HA is inactive against HA-sensitive AtolC E.
coli and Streptomyces lividans, and also lacked the ability to inhibit in vitro protein
synthesis. Hyg21 also phosphorylates methoxyhygromycin A and desmethylene
hygromycin A with similar kcat and Km values to those observed for HA.
Phosphorylation of the naturally occurring isomers of 5"-dihydrohygromycin A and
5"-dihydromethoxyhygromycin A was 8-10 times slower than for the corresponding
non-natural isomers. These studies demonstrate that Hyg21 is an Ophosphotransferase with broad substrate specificity, tolerating changes in the
aminocyclitol moiety more than in the fucofuranose moiety, and that phosphorylation
by Hyg21 is one of several possible mechanisms of self-resistance in S. hygroscopicus
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NRRL 2388. This chapter has been published as a paper in Antimicrobial Agents and
Chemotherapy, 2008, 52 (10), 3580-8.

2.2 Introduction
As described in section 1.5, the hyg21 gene in the hygromycin A (HA)
biosynthetic gene cluster encodes a putative phosphotransferase that may inactivate
HA by O-phosphorylation. To test this hypothesis, a genetic and biochemical
investigation of hyg21 and its gene product was pursued in the present study. This
study showed that hygll is not an absolute requirement for hygromycin biosynthesis
and that Hyg21 is indeed a phosphotransferase that catalyzes the transfer of the yphosphoryl group of ATP to the 2"-hydroxyl group of HA, abolishing its antibacterial
property. The steady state kinetic parameters for turnover of HA and its analogs have
also been determined, which show that Hyg21 can phosphorylate HA and a range of
analogous substrates bearing a fucofuranose moiety.

2.3 Materials and methods
2.3.1 Antibiotics and chemicals
All antibiotics and chemicals were purchased from Sigma-Aldrich (St. Louis,
MO), unless otherwise indicated. Hygromycin A (HA) was kindly supplied by Pfizer
Inc. Analogs of HA, 2a, 3, 4a, and 7 (FIGURE 3) were isolated from the wild type and
a Ahyg26 blocked mutant strain of S. hygroscopicus [40]. Compounds 5 and 6 were
isolated from a hyg6 deletion mutant (see chapter 3). A diastereomeric mixture of 5"dihydrohygromycin A (2a and 2b) was prepared by reduction of HA as described
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previously [40]. A diastereomeric mixture of 5"-dihydromethoxyhygromycin A (4a
and 4b) was prepared from methoxyhygromycin A (3) in the same way. Antibiotic
A201A (8) was a generous gift of Dr. A. Jimenez, Centro de Biologia Molecular
'Severo Ochoa', Madrid. [2-3H] mvo-inositol (20.0 Ci/mmol) was procured from
Moravek Biochemicals (Brea, CA). Primers for PCR were obtained from Integrated
DNA Technologies (Coralville, IA). Enzymes for DNA manipulations were purchased
from New England Biolabs (Beverly, MA). Prestained protein molecular weight
markers used in SDS PAGE analysis were obtained from Bio-Rad (Hercules, CA).

2.3.2 Bacterial strains, plasmids, and culture conditions
Cosmid 17E3, based upon the SuperCosl vector, was the source for hyg21
gene and has been described previously [40]. The pCR4®-TOPO® vector and One
Shot® Machl™-Tl® chemically competent E. coli cells from Invitrogen (Carlsbad,
CA) were used for cloning the hyg21 PCR product. The pET-15b vector from EMD
Biosciences (San Diego, CA) was used for expression of N-terminal His-tagged
Hyg21 protein. The pET-15b vector with 0.5 kb hyg21 ORF was designated as
pET\5b-hyg21. E. coli BL21-CodonPlus(DE3), obtained from Stratagene (La Jolla,
CA), was the expression host for His-tagged Hyg21 protein. E. coli BW25113/pJJ790
(a strain with the X.-RED recombination plasmid), E. coli DH5a/pJJ773 (a strain with
the aac(3)IV apramycin resistance cassette plasmid), and E. coli ET12567/pUZ8002 (a
nonmethylating plasmid donor strain for intergeneric conjugation) have been
described previously, and were provided by the John Innes Institute (UK) [41]. 5.
hygroscopicus NRRL 2388 is the wild type HA producer strain used to generate the
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Ahyg21 mutant in which hyg21 was replaced by the apramycin resistance cassette. The
E.coli AtolC strain was procured from the E. coli Genetic Stock Center at Yale
University. E. coli strains were normally grown at 37°C in Luria-Bertani (LB) medium
supplemented with the required antibiotics. S. hygroscopicus wild type and deletion
strains were propagated on ISP2 medium (0.4% yeast extract, 1.0% malt extract,
0.4% dextrose, 2.0% agar, pH 7.2) at 30°C. Ampicillin (100 ug/ml final
concentration), apramycin (50 ug/mi), carbenicillin (100 ug/ml), chloramphenicol (25
|ig/ml), and kanamycin (50 ug/ml) were used as required.

2.3.3 DNA manipulations and analyses
Plasmid DNA was isolated using QIAprep Spin Miniprep kit from Qiagen
(Valencia, CA). DNA fragments from agarose gels were isolated using Qiagen's
QIAquick Gel Extraction kit. The QIAquick PCR purification kit was used for
cleaning up the PCR product. Genomic DNA from Streptomyces strains was obtained
using the Wizard Genomic DNA purification kit from Promega (Madison, WI).
Automated DNA sequencing was performed at the DNA core facilities at Virginia
Commonwealth University and Oregon Health and Science University. The DNA
sequences were analyzed with Accelrys DS Gene software. The Hyg21 amino acid
sequence was compared with sequences in the public domain using the BLASTP
program at the NCBI server [96]. A motif search was carried out against the PROSITE
database at the Expasy proteomics server [97].
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2.3.4 Cloning of hyg21 and construction of expression plasmid
The 552 bp hyg21 gene was amplified from cosmid 17E3 using the GC-Rich
PCR System from Roche Diagnostics following the manufacturer's instructions.
Primers (5'-CATATGCCGGAAACTTCGTTCCAGGGC-3' and
5'-GGATCCTCAGCCGTTCGCCAGGAT-3') were designed to create an Ndel
restriction site (bold font) at the initiation codon and a BamHI restriction site (bold
font) 3' to the termination codon. Amplification was performed with a GeneAmp PCR
System 2700 (Applied Biosystems) using the following conditions: initial denaturation
at 95 °C for 5 min, 30 cycles of amplification (45 s denaturation at 95 °C, 45 s
annealing at 58 °C, and 45 s extension at 72 °C), and a final 7 min extension at 72 °C.
The PCR product was cloned into pCR4®-TOPO® vector and was sequenced to ensure
that no mutations occurred during amplification. The hyg21 from the recombinant
TOPO vector was then subcloned into the Ndel and BamHI restriction sites of
pET15b. The resulting pET15b-hyg21 plasmid was introduced into the E. coli BL21CodonPlus (DE3) expression host by transformation.

2.3.5 Expression and purification of His-tagged Hyg21 from E. coli
E. coli BL21 cells harboring the pET15b-hyg21 plasmid were grown overnight
in LB medium supplemented with 100 ug/ml ampicillin and 50 ug/ml
chloramphenicol. 1000 ml of LB broth plus ampicillin and chloramphenicol, divided
into two 4-liter fermentation flasks, was inoculated to 5% (v/v) with an overnight
BL21 seed culture. The cells were allowed to grow at 37 °C for ~2 hr until an A6oo nm
of 0.6 was reached. Expression of His-tagged protein was induced by adding 0.5 mM
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isopropyl thio-P-D-galactoside (IPTG) and incubating at 30 °C for 5 hr. The cells were
harvested by centrifugation and resuspended in 25 ml of lysis buffer (50 mM
NaH2P04, 300 mM NaCl, 10 mM imidazole, pH 8.0). His-tagged protein was purified
under native conditions following the procedure outlined in Qiagen's Ni-NTA Spin
protocol. All the protein purification steps were carried out at 4 °C. Cells were
disrupted by sonication and the soluble fraction was applied to 1 ml of Ni-NTA
agarose pre-equilibrated with lysis buffer. The column was washed with 50 ml of
wash buffer (50 mM NaH 2 P0 4 , 300 mM NaCl, 20 mM imidazole, pH 8.0) and the
protein was eluted with elution buffer containing 250 mM imidazole in fractions of
500 |il. Each fraction was analyzed by SDS-PAGE using a 13% acrylamide gel for the
presence of Hyg21. The eluted protein was dialyzed for 14 hr against a buffer
containing 50 mM Tris/HCl (pH 7.5), 20% glycerol, and 5 mM 2-mercaptoethanol,
with a replacement with fresh buffer after 4 hr. Protein concentration was determined
by Bio-Rad protein assay using bovine serum albumin as standard, and 50 ul aliquots
of the purified protein were stored at -80 °C until further use.

2.3.6 Phosphorylation assay conditions
Initial enzyme assays were performed with —10 (ag purified enzyme in a 100 pi
reaction of 50 mM Tris/HCl (pH 7.5), 5 mM 2-mercaptoethanol, 10 mM MgCl2, 200
pM substrate, and 1 mM ATP. The reaction mixture was incubated at 30 °C for 2 hr
and frozen at -20 °C. Hyg21 activity was studied by reverse-phase HPLC analysis by
monitoring the appearance of phosphorylated product, which had a shorter retention
time than the substrate. For kinetics studies, the reaction volume was scaled up to 600
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pi with ~11 (ag of enzyme. The assays were carried out for 15 min, during which
phosphorylation activity was linear. The ATP concentration was fixed at 400 pM and
the antibiotic concentration was varied from 5 uM to 100 pM. To determine kinetic
parameters for ATP and GTP, the concentrations of these were varied and the
concentration of HA was fixed at 90 pM. In all cases the samples were analyzed by
HPLC and the amount of product formed was determined from its peak area using a
HA standard curve as reference. The rate of phosphorylation was reported as the
nmoles of product formed per minute. The data were plotted in GraFit 4 to determine
the kinetic parameters. The pH profile was obtained using 100 uM HA and 1000 uM
ATP at 30 °C for 15 min in the following buffers: 50 mM potassium acetate, pH 5.0;
50 mM Tris/maleate, pH 6.0, 6.5; 50 mM Tris/HCl, pH 7.0, 7.5, 8.0, 9.0. The effect of
temperature on Hyg21 activity was checked using 100 pM HA and 1000 pM ATP in
50 mM Tris/HCl, pH 7.5 at room temperature (23 °C), 30 °C, 37 °C, and 50 °C in a 15
min assay.

2.3.7 Purification and characterization of phosphorylated hygromycin A
Ten reaction mixtures (5 ml each) with a final composition of 200 pM HA,
1000 pM ATP, 10 mM MgCl2, 5 mM 2-mercaptoethanol, and 0.5 mg enzyme in 50
mM Tris/HCl, pH 7.5 were incubated overnight at 30 °C. The assay mixtures were
pooled and filtered using Millex®-LCR 0.45 urn filter unit from Millipore, and the
phosphorylated HA was purified by semipreparative reverse phase HPLC. Fractions
containing the purified product were pooled and dried by evaporation. The dried
sample was dissolved in deuterium oxide for structural elucidation by NMR. *H NMR
33

spectra were recorded on Nicolet NM-500 MHz (modified with a Tecmag Libra
interface) instruments calibrated using residual undeuterated solvent as an internal
reference. 2D COSY correlation spectra were recorded on a Bruker AMX-400 NMR
spectrometer. A standard HA sample was run under identical conditions for
comparison. Coupling constants (/) were expressed in Hertz. Abbreviations for
multiplicities are: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet.

Hygromycin A. lH NMR (500 MHz, D 2 0) 5 7.23 (d, / = 8.5 Hz, 1H), 7.10 (s, 1H),
7.03 (s, 1H), 7.01 (s, 1H), 5.82 (d, J = 4.5 Hz, 1H), 5.25 (s, 1H), 4.92 (s, 1H), 4.73 (m,
1H), 4.58 (t, 7 = 4.5 Hz, 1H), 4.50-4.46 (m, 1H), 4.37-4.35 (m, 1H), 4.31-4.25 (m,
2H), 4.14 (dd, / = 3.5, 9.5 Hz, 1H), 4.02 (dd, J= 5.5, 9.5 Hz, 1H), 3.90 (dd,, J= 3.5,
6.0 Hz, 1H), 2.15 (s, 3H), 2.07 (d,, J= 1.5 Hz, 3H).

Phosphorylated hygromycin A. lH NMR (500 MHz, D 2 0) 5 7.34 (d, J = 8.5 Hz,
1H), 7.16 (s, 1H), 7.08 (s, 1H), 7.06 (s, 1H), 5.95 (d, J = 2.5 Hz, 1H), 5.31 (s, 1H),
4.97 (s, 1H), 4.69 (m, 1H), 4.63 (t, / = 4.5 Hz, 1H), 4.58 (d, J= 6.5 Hz, 1H), 4.36-4.31
(m, 2H), 4.20 (dd, J = 3.5, 9.5 Hz, 1H), 4.08 (dd, J = 5.0, 9.5 Hz, 1H), 3.95 (t, J = 4.5
Hz, 1H), 2.25 (s, 3H), 2.12 (s, 3H).

2.3.8 HPLC and LC-MS conditions
Reverse phase HPLC analyses of the phosphorylation assays and the
fermentation broths were carried out using an Agilent 1100 Series HPLC system with
either an analytical 5 u m Eclipse XDB-C18 (4.6 * 150 mm) column or a

semipreparative 5 p.m Phenomenex CI8 column (250 * 10 mm). Solvents used were A
(10% methanol, 90% water, 0.05% formic acid) and B (90% methanol, 10% water,
0.05% formic acid). Gradient conditions for the analytical column were 100% A for 2
min, 100 - 36% A for 16 min, 36 - 0% A for 2 min, 0% A for 8 min, 0 - 100% A for
2 min, 100% A for 10 min, at a flow rate of 1 ml/min. Gradient conditions for the semi
preparative column were 100% A for 2 min, 100 - 44% A for 16 min, 44 - 0% A for 2
min, 0% A for 6 min, 0 - 100% A for 1 min, 100% A for 5 min, at a flow rate of 3
ml/min. HA and related compounds were detected at 272 nm. Analysis of radiolabeled
HA production by feeding [2-3H] myoinositol was carried out on a Beckman System
Gold instrument equipped with a radiodetector. MS characterization was performed
using a Perkin-Elmer SCIEX API 2000 mass spectrometer in the positive mode.

2.3.9 Targeted gene disruption oihyg21
The hyg21 gene in the wild type was replaced with the apramycin resistance
cassette using the PCR-targeted Streptomyces gene replacement method [41]. The
Expand High Fidelity kit from Roche was used for PCR amplification of apramycin
resistance cassette from pIJ773 with primers /ryg2i_KO_Forw (5'ACCGTTGACCGAGAATGGGTAAAGGAGCAGAAAACAATGA7TCCGGGG
ATCCGTCGACC-y) and hyg21_KO_Revr (5'TCCACCGGGCCCCGCGCGGACCCGCCGCCCGGCGGATCATGrAGGCrG
GAGCTGCTTC 3') (bold font indicates homology to the nucleotide sequence flanking
hyg21 while italicized font is homologous to pIJ773). Gene replacement was carried
out first in cosmid 17E3 and then in the genome of S. hygroscopicus. Gene
35

replacement in the resulting mutant strain, Ahyg21, was confirmed by PCR
amplification of the apramycin cassette from the chromosomal DNA using the outer
primers, /ryg2;_Out_Forw (5'-CCGCTTTCCGTCACAACGGAT-3') and
/ryg2i_Out_Revr (5'-CATGCGCACCTGGCTGAC-3') and by sequencing the PCR
product.

2.3.10 Fermentation conditions for S. hygroscopicus strains
S. hygroscopicus wild type and Ahyg21 mutant strains were cultivated as
reported earlier [39]. Briefly, 50 - 100 ul of spore suspension were inoculated into 50
ml of seed culture medium containing 13.0 g glucose, 7.0 g corn starch, 7.0 g NZ
amine YTT, 3.0 g of corn steep solid, 1.3 g of MgS0 4 . 7H 2 0, 0.7 g of (NH4)2P04, 0.7
g KH2PO4, 2 mg of C0CI2.6H2O, 2 drops of soybean oil, and 1 drop of polypropylene
glycol (P2000) in 1 liter of tap water, pH 7.0. The seed culture was grown for 2 days at
30 °C and 280 rpm, and 4 ml of it was inoculated into 100 ml of production medium
(50 g glucose, 10 g soy flour, 5.0 g of NZ amine YTT, 5.0 g of NaCl, 1.0 g of CaC0 3 ,
2 drops of soybean oil, and 1 drop of P2000 in 1 liter of tap water, pH 7.0). After 6
days of growth at 30 °C and 280 rpm, the mycelium was removed by centrifugation at
10000 rpm for 10 min at 4 °C and the filtered supernatant was analyzed directly by
HPLC. To obtain cell lysates, mycelium was collected from 100 ml of culture,
suspended in 5 ml of methanol and shaken on an orbital shaker at room temperature
for 6 hr. The suspension was then subjected to a brief sonication and cell debris was
removed by centrifugation.
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2.3.11 Feeding of [2-3H] labeled mjo-inositol
Feeding studies using radiolabeled precursors were carried out in 5 ml of
production medium inoculated with 200 |il of seed culture. [2- H] mvo-inositol was
added after 24 hr to a final concentration of 0.4 |iCi/ml.

2.3.12 Assays to test the bioactivity of phosphorylated hygromycin A
The bioactivity of phosphorylated HA (HA-P) was tested by antibiotic
diffusion method using an efflux pump deficient Ato/C E. coli strain as test organism.
15 ml of LB agar was overlaid with 1.5 ml of soft agar (0.3% agar) seeded with 2 ul of
an overnight culture of Ato/C E. coli. Filter paper discs (5 mm diameter) were placed
on the plate, to which 30 (ig and 60 |ag of purified HA-P were applied. Similar
amounts of HA were used as positive control. The plate was incubated for 15 hr at 37
°C and examined for the appearance of zones of inhibition. The assay was also
repeated with S. lividans. 25 jal of spores were spread on ISP2 agar plate and filter
paper discs were placed as before. The plate was examined for zones of inhibition
after 15 hr of incubation at 30 °C.

The ability of HA and HA-P to inhibit protein synthesis was verified by
coupled transcription-translation experiments, which were performed by Daniel
Wilson's group at the Center for Integrated Protein Science, Munich. The assays were
carried out using an E. coli lysate-based system (RTS100 E. coli HY kit from Roche)
for the expression of green fluorescent protein (GFP) in the presence and absence of
antibiotics [98, 99]. GFP was quantitated under native and denaturing conditions using
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ImageQuaNT (Molecular Dynamics, Inc.) and represented graphically using
SigmaPlot (Systat Software, Inc.).

2.3.13 Hygromycin sensitivity of S. hygroscopicus and the Miyg21 strain
The MIC95 of HA for wild type and Ahyg21 mutant was determined by the
agar plate dilution method. 30 |il of spore suspensions of both the strains (2000
CFU/ml) (CFU - colony forming unit) were plated on 3 ml ISP2 agar plates containing
200 ug/ml, 300 (ig/ml, and 400 pg/ml of the antibiotic. The plates were incubated at
30 °C for 48 hr. The MIC95 was the lowest concentration of HA that prevented visible
growth of 95% or more of the CFUs on the plate.

2.4 Results
2.4.1 Sequence analysis of Hyg21
The hyg21 ORF is 552 nucleotides long with a putative translation product of
183 amino acids and a theoretical molecular weight of 19.87 kDa. A search of the
NCBI protein sequence database using the web-based BLASTP program revealed that
the deduced amino acid sequence has highest similarity of 73% to the Ard2 protein
from Saccharothrix mutabilis subsp. capreolus, the producer of antibiotic A201A
(compound 7) (FIGURE 3). A201A is structurally homologous to HA, and cell free
extracts from S. capreolus wild type and S. lividans harboring a recombinant Ard2
have been shown to phosphorylate A201A at the C-2 hydroxyl of the hexafuranose
moiety leading to loss of antibiotic activity [100]. There have been no published
reports of purification or characterization of Ard2. No significant overall similarity of
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Hyg21 to any other known antibiotic modifying kinases could be detected. A
BLAST/Conserved Domain search instead retrieves the gluconate kinase domain
proteins, indicating that Hyg21 and Ard2 may represent a new class of antibiotic
modifying kinases. A search of PROSITE protein domain database indicated the
presence of a ATP/GTP binding site motif, also known as Walker A motif or P-loop,
[(A/G)XXXXGK(S/T)], near the Af-terminus of Hyg21 within residues 24-31
(GIPGSGKS) [97]. This glycine-rich motif is often found in nucleotide-binding
proteins and is known to form a flexible loop that interacts with ATP or GTP [101,
102]. On the basis of these observations, it is hypothesized that the hyg21 gene
encodes a kinase involved in (^-phosphorylation of HA.

2.4.2 Hyg21-catalyzed phosphorylation of hygromycin A
The PCR amplified hyg21 ORF was cloned into E. coli expression vector
pET15b to give the pET15b-Avg2i plasmid and overexpressed in BL21-CodonPlus
cells as an JV-terminal His6-tagged protein. A large fraction of the expressed protein
formed inclusion bodies under the given expression conditions but it was possible to
recover substantial amounts of soluble protein using a 1-liter culture and affinity
chromatography purification on a Ni-NTA agarose column. SDS-PAGE analysis of
the purified preparation demonstrated a prominent protein band with a relative
molecular mass of 22 kDa, consistent with the mass of Hyg21 (~20 kDa) containing a
hexahistidine tag (~2 kDa) (FIGURE 11).
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FIGURE 11. SDS PAGE analysis of Hyg21 from Ni-NTA purification.
Lane M - Standard protein marker; Lanes E1-E4 - Hyg21 elution fractions
In order to determine the biochemical function of Hyg21, the recombinant
protein was incubated with HA and ATP at 30 °C for 2 hr. Reverse-phase HPLC
analysis of the reaction mixture after incubation revealed a significant decrease in the
HA peak and the appearance of a new peak with a shorter retention time (FIGURE
12B). In a control incubation without Hyg21, this new peak was absent and the levels
of HA did not alter (FIGURE 12A). The shorter retention time for the new peak was
consistent with increased polarity of HA through addition of a phosphoryl group.
Mass spectrometric analysis of the reaction mixture showed that the compound under
the new peak had a molecular mass of 592 ([M+H]+) (FIGURE 12C). This increase of
80 AMU from that of HA (512 [M+H]+) corresponds to the addition of a single
phosphoryl group to the molecule. These data support the hypothesis that hyg21
encodes a phosphotransferase that carries out mono-phosphorylation of HA.

FIGURE 12. Reverse phase HPLC - MS analyses of phosphorylation of
hygromycin A by Hyg21. Panel A.- HPLC chromatogram of a control reaction of
hygromycin A (HA) and ATP without Hyg21. Panel B - HPLC chromatogram of a
reaction of hygromycin A and ATP after incubation with Hyg21. The resulting
phosphorylated HA (HA-P) product has a shorter retention time than HA under the
tested HPLC conditions. Panel C represents mass spectral analysis (in positive mode)
of the HA-P.

The presence of 5 mM 2-mercaptoethanol in assays of Hyg21 was found to be
necessary for maintaining optimal activity. The optimal pH for Hyg21 activity was
measured across a range of pH values from 6 to 9 (FIGURE 13A). The fastest rate of
reaction, determined by the amount of product formed per min, was in the range of pH
7.5 and 8. Activity was markedly decreased at lower pH values and almost absent at
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pH 5. The effect of temperature on activity was also studied across a range of 23 °C
50 °C. In a 15 minute assay, product formation was maximal at 30 °C. The enzyme
retained two-thirds of its activity at room temperature and 37 °C, but very little at
50°C (FIGURE 13B).
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FIGURE 13A. pH dependence of Hyg21 activity.
Assays were done with 100 uM HA and 1000 uM
ATP at 30 °C for 15 min and the amount of
phosphorylated HA (HA-P) was determined.
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FIGURE 13B. Temperature dependence of
Hyg21 activity. Assays were done with 100
uM HA and 1000 uM ATP at pH 7.5 for 15
min and the amount of phosphorylated HA
(HA-P) was determined.
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2.4.3 Activity of phosphorylated HA
The activity of phosphorylated HA (HA-P) was tested in a disc diffusion assay
against HA-sensitive AtolC E. coli strain that has an impaired efflux mechanism due
to the absence of the outer membrane component of the efflux pump [103]. As seen in
FIGURE 14A, distinct zones of inhibition were seen with HA. In contrast, no zones of
inhibition were seen with the phosphorylated HA even at 60 u.g. Similar observations
of antibacterial activity for HA but not HA-P were observed in disc diffusion assays
against HA-sensitive Streptomyces lividans. HA-P was also tested for its ability to
inhibit in vitro protein synthesis in a coupled transcription-translation assay. The IC50
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and IC90 of HA-P for green fluorescent protein synthesis inhibition were observed to
28 p.M and 70 p.M, respectively. These values are 13-16 times higher than those for
HA, which showed an IC50 of 2.2 [iM and an IC90 of 4.2 uM. These observations are
consistent with the hypothesis that phosphorylation abolishes the antibiotic potency of
HA and also indicate the likely function of hyg21 as a self-resistance determinant in S.
hygroscopicus NRRL 2388.

30 M!i HA

60 MSI HA

a.
30 (is HA-P

60 uz HA-P

* -«»*
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o

40
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Antibiotics [pM]

FIGURE 14. Activity of hygromycin A (HA) and its phosphorylated form (HAP). A. Filter paper discs with HA or HA-P were placed on agar plate seeded with
AtolC E. coli. Only HA and not HA-P showed bioactivity, as indicated by the absence
of growth around the filter paper discs with HA-P.
B. In vitro green fluorescent protein synthesis was carried out in the presence of HA
and HA-P. The IC50 of HA-P was 15 times higher than that of HA.
2.4.4 Site of phosphorylation in HA
X

H NMR analyses of purified HA (5 mg) and HA-P (2 mg) were carried out to

determine the site of phosphorylation by Hyg21. The chemical shifts of the two
samples were virtually identical, with the exception of the proton signal for the C2"
methine (H2"), which is shifted downfield from 8 4.36 ppm for HA to 8 4.69 ppm in
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HA-P. In each case the H2" assignment was confirmed by a COSY experiment, which
revealed a strong cross peak with the distinctive anomeric HI" resonance (FIGURE
15). The chemical shift change for the H2" alone is consistent with phosphorylation
of the C2" hydroxyl substituent.
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FIGURE 15. Expansion of 2D "H-H
COSY spectra of hygromycin A (A) and its
phoshorylated form (B) in D2O.

2.4.5 Substrate specificity of Hyg21
The substrate specificity of Hyg21 was explored by carrying out enzyme
assays with various analogs of HA (2-6), A201A (8), and puromycin (9) (FIGURE 3).
HPLC-MS analyses revealed that, with the exception of 9, all of these compounds
were partially or completely converted to new products with shorter retention times
and with masses increased by 80 AMU (TABLE 2). Notable among these observations
was that antibiotic A201A (8), which is much larger than HA but has structurally
similar fucofuranose and (£)-3-hydroxyphenyl)-2-methylacrylic acid moieties, was
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also a substrate for Hyg21. In addition, 7, which lacks the aminocyclitol and thus is
significantly smaller than HA, is also a substrate. In both cases the substrate contains a
fucofuranose with a C2-hydroxyl substituent. This moiety is missing in 9, despite its
structural similarities with both HA and A201 A, and in this case phosphorylation with
Hyg21 is not observed. These observations demonstrate that Hyg21 exhibits broad
substrate specificity and that the fucofuranose moiety with C2-hydroxyl group is a key
structural element required for phosphorylation. The latter inference is consistent with
the observation that in HA, Hyg21 catalyzes phosphorylation at C2 of this moiety.

HA phosphorylation was also carried out by substituting ATP with guanosine
triphosphate (GTP), thymidine triphosphate (TTP) and cytidine triphosphate (CTP).
Besides ATP, product formation was seen only with GTP. There was no reaction with
either TTP or CTP.

The rate of phosphorylation for different substrates was determined by
measuring the amount of product formed per minute (TABLE 2). The reaction was
linear during the first 15 min of incubation under the given assay conditions. Under
these conditions kcat values of 2.2 min"1 and Km values of approximately 30 uM were
obtained for HA (FIGURE 16). The enzyme had a lower Km value for ATP than for
GTP (FIGURE 17). Similar but slightly slower k^t rates were observed for ATPdependent phosphorylation of 3 and 5 by Hyg21. These data and similar Km values
indicated that the methylene group of HA, which is present as a methyl group in 3 and
absent in 5, is not important for binding and catalysis.
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TABLE 2. Summary of the kinetic data for Hyg21 phosphorylation
„ , . .
Substrate
(see FIGURE 3 for structures)

Substrate

Product

[M+H]+

[M+H]+

,
K-^,
(nun'1)

Hygromycin (HA)

512

592

2.2

„
Km
(" M )
29.2 + 4.4

Methoxyhygromycin A (3)

514

594

2.0

29.7 + 5.8

Desmethylenehygromycin A (5)
5"-Dihydrohygromycin A
(Natural isomer) (2a)
5"-Dihydrohygromycin A
(Non-natural isomer) (2b)
5"-Dihydromethoxyhygromycin A
(Natural isomer) (4a)
5"-Dihydromethoxyhygromycin A
(Non-natural isomer) (4b)
5"-Dihydrodesmethylenehygromycin
A (Natural isomer) (6)
5"-Dihydro AB subunit (7)

500

580

1.9

35.6 ±.3.9

514

594

0.2

8.5 + 5
:.0

514

594

1.6

16.5 +:2.8

516

596

0.13

10.0 + 2.6

516

596

1.3

12.3 ±.1.8

502

582

ND*

ND

363

443

ND

ND

A201A (8)

803

883

ND

ND

ATP

198.3 ±19.1

GTP

356.5 + 62.1

* ND - Not determined

kcat (min-1) = 2.0
Km(nM) =29.7 + 5.8

kcat (miir1) = 2.2
KmQjM) =29.2 + 4.4
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FIGURE 16. Kinetic analysis of Hyg21 using varying concentrations of HA, 3, or
5, and 400 uM of ATP.
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FIGURE 17. Kinetic analysis of Hyg21 using varying concentration of ATP or
GTP, and 90 uM of HA.
Compounds 2a (a 5"-dihydro analog of HA) and 4a (a 5"-dihydro analog of
methoxyhygromycin A, 3) have previously been identified in fermentation of the
Ahyg26 S. hygroscopicus mutant [40]. A diastereomeric mix of 2a and the other 5"dihydroisomer (2b) was produced by chemical reduction of HA. HPLC analysis of
Hyg21-catalyzed phosphorylation of this mixture revealed much faster reaction rates
with 2b than with 2a (FIGURE 18). Apparent kinetic values for the reaction of each
isomer in the mixture were obtained, which revealed that 2b was processed with
similar reaction rate (kcat 1.6 min"1) to HA, 3, and 5. In contrast, the reaction rate is 8fold slower (kcat 0.2 min"1) with the isomer 2a, which appears to be either a shunt
metabolite or an intermediate in the HA biosynthetic pathway (see chapter 4) (TABLE
2) (FIGURE 19).

A similar set of observations was made with a diastereomeric mixture of 4a
and 4b (obtained by chemical reduction of 3). The phosphorylation rate for the 4a
48

isomer is slow (kcat 0.13 min"1), but much faster (kcat 1.3 min"1) for 4b (TABLE 2)
(FIGURE 19).
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FIGURE 18. Hyg21-catalyzed phosphorylation of a diastereomeric mixture of
5"-dihydrohygromycin A (2a and 2b). Panel A - HPLC chromatogram of a control
reaction of dihydrohygromycin A and ATP without Hyg21. Panel B - HPLC
chromatogram of a reaction of dihydrohygromycin A and ATP after incubation with
Hyg21. 2a is the naturally occurring isomer also detected in fermentation broths of the
wild type and the hyg26 blocked mutant. 2b is the non-natural isomer observed only in
the diastereomeric mixture after chemical reduction of HA. The phosphorylated
products of 2a and 2b are labeled as 2a-P and 2b-P respectively.
In contrast to the k^t values, much smaller changes in Km were observed for the
various substrates. These kinetic data indicate that Hyg21 can process HA analogs in
which the 5"-keto group is reduced, but the efficiency of the process is determined by
the stereochemistry at the C5". Kinetic studies for substrates 6, 7, and 8 were
precluded because of low availability of the substrates and/or presence of impurities.
A comparison of reaction completion with HA and 8 carried out under standard
conditions indicated that the rate of conversion of 8 was at least 5-fold slower.
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FIGURE 19. Kinetic analysis of Hyg21 with natural and non-natural 5"-dihydro
compounds.
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2.4.6 Generation and analysis of a Ahyg21 S. hygroscopicus mutant
The hyg21 gene in S. hygroscopicus was replaced with the apramycin
resistance gene to assess its role in HA biosynthesis and resistance. A gene
replacement strategy was used because the hyg21 is well-separated from its flanking
genes, and its orientation relative to these indicates that it is not part of a polycistronic
transcript (FIGURE 20).

hyg20

^

^ hyg21
63 bp

Jm2^^

hyg22
265 bp

ffgffiyVw

^hyg22

FIGURE 20. Schematic representation of hyg20-22 region in the genome of S.
hygroscopicus wild type (Panel A) and Miyg21 mutant (Panel B). The hyg20 and
hyg22 gene products are homologous to transglucosylases and acyltransferases
respectively, and have been proposed to be involved in HA biosynthesis. The hyg21
gene is replaced with the apramycin resistance gene, aac3(IV), in Ahyg21 strain.
The tshyg21 mutant strain was cultured and the fermentation broth was
analyzed for the production of HA. HA was detected indicating that hyg21 was not
essential for the biosynthetic process. Nonetheless, the yields were dramatically
reduced (>90%) from the 0.8 g/L of HA obtained in the wild type strain. Detailed LCMS analyses of fermentation broth of Ahyg21 also revealed the presence of 3, 4a, 5
and 6. The same compounds could be detected by radioactive scintillation counting
when the mutant was grown in the presence of tritiated myoinositol (which is
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converted into the aminocyclitol portion of HA) (FIGURE 11). While the levels of 3,
4a, 5 and 6 could not be quantitated, the analyses indicated that they were similar in
both the wild type and Ahyg21 mutant, contrasting the observations made for the
levels of HA.

FIGURE 21. Reverse-phase HPLC analyses and radiolabel detection of wild type
and Ahyg21 culture broths grown in the presence of [2-3H] myo -inositol.
Production of hygromycin A (HA) was significantly decreased in the mutant.
Radiolabeled analogs of HA are present in fermentation broths of both the wild type
and Ahyg21 strains (see FIGURE 3 for structures).
The low amounts of HA in the fermentation broth of Ahyg21 raised the
possibility that it is HA-P that is exported from S. hygroscopicus by an efflux pump
and subsequently converted to HA by an extracellular phosphatase. In such a case HA
might be expected to accumulate inside the cells of Ahyg21. To investigate this
possibility the mycelium of Ahyg21 was lysed by methanol treatment and the lysate
was analyzed by HPLC. However, HA could not be detected in the cell lysate and it
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was estimated that nearly all of the HA made by this strain is found in the
fermentation broth. Also, no HA-P could be detected in either the cell lysate or the
fermentation broth of the wild type strain. An agar plate dilution assay was carried out
to assess whether the Ahyg21 strain had increased sensitivity to HA as compared to
the wild type strain. The MIC95 for both the strains was found to be 400 ug/ml.

2.5 Discussion
Analysis of the deduced amino acid sequence of the hyg21 gene in the HA
biosynthetic gene cluster led to a hypothesis that it encodes a protein that
phosphorylates HA and thus provides a resistance mechanism to the producing
organism by antibiotic inactivation. The first component of this hypothesis has been
unequivocally verified by in vitro assays in which Hyg21 phosphorylated HA
selectively at the C2"-OH position. Hyg21 also phosphorylates a number of HA
analogs, and the site of modification in these may also be the C2"-OH. Some of these
analogs are observed at various levels in fermentations of the wild type S.
hygroscopicus [39, 40]. It was also observed that these analogs, in particular
methoxyhygromycin A and desmethylenehygromycin A, have some level of
antibacterial activity, albeit less than that observed for HA. Presumably, resistance to
these compounds as well as HA can be provided in part by the Hyg21-catalyzed
phosphorylation.

Although Hyg21 phosphorylated HA, the rate of reaction was very slow (kcat of
~2 min"1). Analyses of S. hygroscopicus fermentations reveal that the majority of the
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HA product is found in fermentation media indicating an efficient export process. No
evidence for any HA-P in the fermentation broth or in the cell lysate is seen, and
sequence analyses of the HA biosynthetic gene cluster to date have not revealed a
candidate phosphatase that would convert HA-P to HA (the hyg25 gene product
appears to be involved in conversion of mvo-inositol-1-phosphate to mvo-inositol, a
step in the biosynthesis of the aminocyclitol moiety of HA, chapter 3). Thus, all
evidence indicates that it is HA that is exported and that HA-P may be generated from
residual HA in the cell. In such a case, a slow rate of phosphorylation by Hyg21
would allow most of the HA biosynthetic product to be exported rather than become
trapped intracellularly as HA-P.

The results from these studies do not provide unequivocal evidence for the
hypothesis that phosphorylation of HA is a resistance mechanism in the producing
organism. It is observed that HA and not HA-P has antibacterial activity against other
bacteria. The loss of antibacterial activity has further been shown to be due to
inhibition of binding to the ribosomal target than due to poorer penetration into the
organisms. However, the Ahyg21 mutant retains significant resistance to HA. This
observation likely reflects the presence of other operational mechanisms of resistance.
The most likely of these are methylation of the ribosomal RNA, catalyzed by the
hyg29 gene product, and an efficient HA export process, catalyzed by the hygl9 and
hyg28 gene products. Characterization of the remaining putative resistance
determinants in the HA biosynthetic gene cluster are reported in the later part of this
thesis. Finally, the observation that insertional inactivation of hyg21 reduces the
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production of HA to almost negligible amounts is curious. A polar effect from
replacement of the gene cannot be ruled out, but seems unlikely given the strategy
used and the organization of genes surrounding hyg21 (FIGURE 20). This result was
consistently observed in all the four mutant colonies that were examined. A significant
decrease in HA production would be predicted in this mutant if the Hyg21-catalyzed
phosphorylation process occurred at an earlier step in the biosynthetic process, with
the later stages occurring with phosphorylated intermediates. Early modification
would ensure that the resistance mechanism is in operation prior to assembly of the
final product and has precedent in the biosynthesis of streptomycin and paromomycin
[44, 45]. The slow turnover of HA might also indicate that a pathway intermediate,
and not the final product, may be the preferred substrate for Hyg21. However, there is
no genetic evidence for a phosphatase that would be responsible for the conversion of
HA-P to HA, and HA-P is not detected in fermentations of the wild type strain. These
observations argue against Hyg21-catalyzed phosphorylation of a pathway
intermediate as a step in the biosynthetic process. In the case of tylosin biosynthesis it
has been shown that disruption of any of the four genes involved in the biosynthesis of
the mycaminose sugar, which is the first sugar that gets attached to tylactone (the
polyketide aglycone), abolishes not just tylosin production but also the accumulation
of tylactone [104]. In a similar way, HA-P may be required for stimulating the HA
biosynthetic pathway by positive feedback regulation, accounting for the decreased
production in the Ahyg21 mutant.
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In conclusion, it has been shown in this study that Hyg21 catalyzes
phosphorylation of HA and related compounds, leading to loss of antibacterial activity
due to poorer binding to the ribosomes. Thus, hyg21 is the first of the several possible
resistance determinants in S. hygroscopicus NRRL 2388 that has been functionally
characterized. The roles of Hyg6 and Hyg29 (methyl transferases), and Hygl9 and
Hyg28 (antibiotic efflux proteins) as additional resistance determinants are described
in the subsequent sections of this thesis.
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3. Characterization of two methyltransferase homologs, hyg6 and hyg29, from the
biosynthetic gene cluster of hygromycin A

3.1 Summary
Hygromycin A (HA) exerts its antibiotic activity by binding to the 23S rRNA
and inhibiting the peptidyl transferase reaction. The structure of HA is characterized
by the presence of a methylene bridge between the C4 and C5 hydroxyl groups in the
aminocyclitol subunit, which is derived from S-adenosylmethionine. The gene cluster
for HA biosynthesis contains two methyltransferase homolog genes, hyg6 and hyg29.
Targeted disruption of hyg6 abolished the production of HA and methoxyhygromycin
A. Instead, the hyg6 mutant strain produced two new metabolites, desmethylene
hygromycin A and 5"-dihydrodesmethylenehygromycin A, which lacked the
methylenedioxy bridge. The structures of the desmethylene compounds were
confirmed by mass spectrometry and NMR analysis. Antibacterial activity assays
against an efflux pump-deficient E. coli strain (AtolC E. coli) showed that the
biological activity of desmethylenehygromycin A was 15 times reduced in comparison
to HA. This activity is comparable to that of methoxyhygromycin A, indicating that an
intact methylenedioxy bridge is essential for optimum antibacterial activity. At the
same time, the in vitro protein synthesis inhibition activity of desmethylene
hygromycin A was nearly 4 times greater than that of HA or methoxyhygromycin A,
suggesting that the loss in biological activity due to disruption of the methylenedioxy
ring is likely to be due to reduced uptake of the compounds into the cell and not due to
their inability to bind to the ribosomes. Disruption of hyg29 did not affect the
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resistance of S. hygroscopicus to HA or the antibiotic production profile, although the
antibiotic yield was reduced. Ribosomal RNA methylation is a possible route of selfresistance in S. hygroscopicus, which could be performed by the hyg29 gene product.
It is currently not known whether the ribosomes of S. hygroscopicus are modified or
not, but the results of hyg29 disruption indicate that this gene is dispensable for
antibiotic production and resistance, presumably due to the presence of other putative
self-resistance determinants.

3.2 Introduction
Bacteria protect themselves from ribosome-targeting antibiotics chiefly by 1)
mutations in the genes for ribosomal RNA (rRNA) or ribosomal proteins, or 2) by
methylation of rRNA at specific positions. Genes for rRNA methylases conferring
intrinsic resistance are frequently found in the biosynthetic gene clusters of antibiotics
that bind to the ribosome. Macrolide antibiotics such as erythromycin, clarithromycin,
oleandomycin, pikromycin, and tylosin bind to the 50S ribosomal subunit The crystal
structure of the 50S ribosomal subunit complexed with macrolides revealed the
manner in which the macrolactone and the sugar substituents of the antibiotic interact
with the ribonucleotides lining the binding pocket in 23S rRNA [105-107].
Specifically, the 2'-hydroxyl and the 3'-dimethylamino groups of the common
desosamine sugar make hydrogen bonds with Nl and N6 of A2o58 in 23S rRNA.
Mono- or dimethylation of the exocyclic amine at N6 of A2058 results in loss of these
contacts and prevents drug binding, leading to resistance. The rRNA methylases in
macrolide producers use S-adenosylmethionine as methyl group donor and are either
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constitutively or inducibly expressed. In S. fradiae, the producer of tylosin, expression
of the genes encoding the TlrA dimethyltransferase, acting on A2058> and the TlrB
monomethyltransferase, which methylates G748, is induced by tylosin, whereas the
tlrD gene for a A2058-monomethyltransferase is constitutively expressed [56, 57, 59].
A stepwise response to tylosin was proposed to explain the presence of multiple rRNA
methylases in S. fradiae [59]. A2058 monomethylation by the constitutively-expressed
tlrD provides protection from low amounts of tylosin diffusing in from older
mycelium. When tylosin production begins in the local regions of the mycelium,
expression of tlrB is induced, leading to G748 methylation and enhanced resistance.
Further increase in tylosin production induces tlrA expression and A2058 dimethylation,
resulting in maximum resistance.

A different category of methyltransferases associated with antibiotic gene
clusters is comprised of those that modify the structure of the antibiotic by
methylation, such as the post-polyketide synthase (post-PKS) methyltransferases.
Depending on the site of reaction, these enzymes are classified as 0-, N-, or Cmethyltransferases. Methylation can take place either on the polyketide backbone or
on the non-PKS moieties such as sugars before or after their attachment to the PKS
core. Multiple methyltransferases are functional in the biosynthesis of tylosin. An Nmethyltransferase, TylM, dimethylates the 3-amino group during biosynthesis of the
mycaminose moiety of tylosin, while a C-methyltransferase, TylCIII, acts on the
mycarose moiety [108]. While these enzymes act before glycosyl transfer onto the
lactone occurs, there are additional methylases that catalyze Omethylation in the final
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two steps of tylosin biosynthesis, and thus can be called true post-PKS enzymes.
Demethylmacrocin (9-methyltransferase methylates the C2'" hydroxyl and converts
demethylmacrocin to macrocin, the penultimate product in tylosin biosynthesis [109].
Macrocin is acted upon by macrocin O-methyltransferase at C3'" hydroxyl to form
tylosin [110]. Both these enzymes are highly selective for their respective substrates
and neither of them is capable of methylating the alternative demethylated compound,
an observation that established that the 2"'-0-methylation step precedes 3"'-0methylation. In biosynthesis of tetracenomycin, three consecutive S AM-dependent
methylations take place on the polycyclic aromatic scaffold. A C3 0-methyl
transferase, TcmN, transforms tetracenomycin D3 to tetracenomycin B3, which is
further O-methylated at C8 by TcmO into tetracenomycin E. A different enzyme,
TcmP, now carboxymethylates tetracenomycin E and forms the penultimate
biosynthetic product, tetracenomycin A2 [111, 112].

Heterologous expression and gene inactivation experiments of methylases have
been carried out to verify their roles in self-resistance and antibiotic biosynthesis, and
also to produce intermediates or analogs with higher biological activity. The latter
objective has been achieved in the case of avermectin biosynthesis in S. avermitilis.
The avermectins are produced as a mixture of two categories of compounds - the A
components that have a methoxy group at C5, and the B components with a C5
hydroxyl group. The unmethylated B components have higher biological activity than
the methylated A compounds. Conversion of the B type to the A type is catalyzed by
avermectin B 5-0-methyltransferase encoded by the aveD gene. When an insertional
60

inactivation of aveD was performed, it resulted in a mutant strain that accumulated
only the more active avermectin B components [113, 114].

As described in chapter 1, hygromycin A (HA) prevents protein synthesis by
inhibiting peptidyl transferase reaction [30]. RNA footprinting experiments showed
that HA binds in the central loop region of domain V of 23S rRNA, which is the
region for peptidyl transferase activity [31]. Sequence analysis of the biosynthetic
gene cluster of HA identified hyg6 and hyg29 as putative methyltransferase genes
[40].

Since HA binds to the ribosomes, it is hypothesized that rRNA methylation by
the activity of either the hyg6 or hyg29 gene products may exist as a self-resistance
mechanism in S. hygroscopicus. The aminocyclitol moiety of HA has a unique
methylene bridge between the C4 and C5 hydroxyl groups, whereas the non-bridge
analog, methoxyhygromycin A (3), has a methoxy group at C5 (FIGURE 3). Feeding
studies had indicated that the methylene bridge was derived from 5-adenosyl
methionine and it was proposed that the bridge formation involves methylation of the
C5 hydroxyl group of neo-inosamine 2 by a SAM-dependent methyltransferase,
followed by cyclization [39]. Thus, either hyg6 or hyg29 is hypothesized to encode a
C5 0-methyltransferase acting on the aminocyclitol. In the present chapter, the results
of targeted gene disruption experiments performed to verify the proposed roles of
hyg6 and hyg29 are reported. The study revealed that methylation of the C5 hydroxyl
group is performed by Hyg6 and not by Hyg29. An analog of HA without the
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methylenedioxy bridge, produced by the Ahyg6 mutant, was observed to have
significantly reduced antibacterial activity, but retained considerable in vitro protein
synthesis inhibition activity. Disruption of hyg29 showed that it is not essential for
antibiotic production or self-resistance of S. hygroscopicus.

3.3 Materials and methods
3.3.1 Chemicals, bacterial strains and growth conditions
All chemicals were purchased from Sigma unless stated otherwise.
Hygromycin A and 2L-2-amino-2-deoxy-4,5-0-methylene-neo-inositol (C subunit)
were kindly supplied by Pfizer Inc. The SuperCosl vector-derived cosmids 17E3 and
15A10 were the sources for hyg6 gene and hyg29 gene, respectively. Ahyg6 and
Ahyg29 are mutant strains derived from S. hygroscopicus wild type in which the
respective genes have been replaced with the apramycin resistance cassette.
Fermentation conditions for S. hygroscopicus strains are described in section 2.3.10.
The Ahyg6 strain was fed with the C subunit by adding the compound after 24 hr of
fermentation to a final concentration of 5 mM. The AtolC E. coli strain was procured
from the E. coli Genetic Stock Center at Yale University.

3.3.2 Targeted disruption of hyg6 and hyg29 genes
The hyg6 and hyg29 genes were independently replaced with the apramycin
resistance cassette using the PCR-targeted Streptomyces gene replacement method
[41]. The gene knockout primers and outer primers for verification of the gene
disruption are given in TABLE 3. Because of the 8 nucleotide overlap between hyg6

and the succeeding hyg7 gene, only 705 out of 750 bases of hyg6 were targeted.
Similarly, in order to not affect hyg28, with which hyg29 shares 68 bases, only 1007
out of 1137 nucleotides of hyg29 were replaced with the apramycin resistance cassette
(FIGURE 22). The resulting mutant strains were termed Ahyg6 and Ahyg29. The DNA
sequence data were analyzed with Accelrys DS Gene software. Public domain
sequence database searches were performed using tools at the NCBI server and at the
Expasy proteomics server.

TABLE 3. Primers used for disruption of hyg6 and hyg29
Primers for hyg6 gene disruption
5' CGCCCCTCGACCGCGAAGACCTTCTGGGGGCAGCGGATGA7TC
yg
~ ~ W
CGGGGATCCGTCGACC-y
5'ATGGTGGTCCGGCCTCCTCGTGTCGTCTGCGTGCCACTGrGrA
frygo_KU_Kevr
GGCTGGAGCTGCTTC-3'
Outer primers for verification of hyg6 gene disruption
A>#5_Out_Forw
5'-CTCGCGCAACGCCTGCGCCA-3'
hyg6_Out_Revr

5'-GCCGTGGTTGACCGCGACG-3'

Primers for hyg29 gene disruption
5GCCGCCCGACCCGAGGCGCCCGGAGACGCCGCCGCGATGA7T
hygM_XJJ_boTW
CcGGGGATCCGTCGACC-3'
5' GCCGTCCGGCCTCTGTGGACCAGCTGTGCGCCGCCTCCATGTA
hygZ9_KU_Kevr
GGCTGGAGCTGCTTC-y
Outer primers for verification of hyg29 gene disruption
hyg29_Out_Forw
5'-CTGGAGGGAGACCCTCGTGG-3'
/jyg29_OutJRevr

5' -CGCGCCCGGAC AACGGTCCC-3'

Bold font indicates homology to the nucleotide sequence flanking hyg6 or hyg29 while italicized font is
homologous to pIJ773 plasmid bearing the ApraR cassette.

3.3.3 HPLC/MS analysis and quantitation of antibiotic production yields
Reverse phase HPLC analysis of fermentation broths of S. hygroscopicus
strains were carried out using a methanol-water gradient system as described in
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section 2.3.8. Mass spectrometric analysis was carried out in negative mode on a
Bruker Daltonics MicroTOF-Q system. For a quantitative analysis of production of
HA and its analogs, cultures of the wild type and mutant strains were set up in
triplicate. Using HA provided by Pfizer Inc, a standard curve was generated of peak
area vs amount in ug with a range between 5 jag and 50 ug. 50 |ul of filtered
fermentation broth from each culture were injected. The amounts of HA and related
products in each injection sample were determined from their individual peak areas
using the standard curve as reference and extrapolated to estimate the total production
per liter of fermentation.

3.3.4 Extraction and characterization of desmethylene analogs
For extraction of desmethylene compounds, Amberlite XAD-4 (Sigma) was
added to the fermentation broth of Ahyg6 (1:20 ratio by volume) and stirred overnight
at 4 °C. The XAD column was washed first with water and then with methanol to
elute the bound compound. The eluted fraction was concentrated by evaporation and
the solid was re-dissolved in methanol. Further purification was carried out by
semipreparative HPLC (see section 2.38). !H-NMR spectra were recorded on a Bruker
AMX-400 NMR. 2D COSY correlation spectra were recorded on a Bruker AMX-600
NMR spectrometer. Coupling constants (7) were expressed in Hertz. Abbreviations for
multiplicities are: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet.

Hygromycin A (1). >H-NMR (400 MHz, D 2 0) 5 7.10 (1H, d, J= 8.0, H-9'), 7.01 (1H,
s, H-3'), 6.88 - 6.91 (2H, m, H-5', H-8'), 5.69 (1H, d, 7 = 4.4, H-l"), 5.18, 4.83 (2H, 64

OCH 2 0-), 4.50 - 4.48 (1H, m, H-2), 4.40 - 4.18 (5H, m, H-2", H-4", H-4, H-5, H-6),
4.08 (1H, t, 7= 2.8, H-3"), 3.95 (1H, dd, J= 5.2, H-l), 3.82 (1H, dd, J= 3.6, H-3),
2.16 (3H, s, H-6"), 2.02 (3H, s, a-CH3).

Desmethylenehygromycin A (5). !H-NMR (400 MHz, D 2 0) d 7.14 (1H, d, J = 8.4,
H-9'), 6.99 (1H, s, H-3'), 6.94 (1H, s, H-5'), 6.93 (1H, d, 7 = 8.4, H-8'), 5.72 (1H, d, /
= 4.4, H-l"), 4.74 - 4.62 (1H, m, H-2), 4.41 - 4.40 (2H, m, H-3", H-4"), 4.30 - 4.22
(1H, m, H-2"), 4.02 (1H, t, / = 2.8, H-5), 3.95 - 3.92 (2H, m, H-l, H-3), 3.72 (2H, dd,
/ = 10.0, 2.8, H-4, H-6), 1.99 (6H, s, a-CH3, H-6").

5"-Dihydrodesmethylenehygromycin A (6). ^ - N M R (D 2 0, 400 MHz) S 7.17
(lH,d, J= 8.2, H-9'), 7.08 (1H, s, H-3'), 7.01 (1H, s, H-5'), 6.99 (1H, d, 7= 8.2, H-8'),
5.69 (1H, d, / = 4.4, H-l"), -4.7 (1H, partially obscured by solvent peak, H-2), 4.334.29 (2H, m, H-2", H-3"), 4.11 (1H, t, / = 2.8, H-5), 4.03 (2H, dd, J = 10.0, 4.2, H-l,
H-3), 3.87-3.80 (3H, m, H-4, H-6, H-5"), 3.74 (1H, t, 7= 6.0, H-4") 2.08 (3H, s, aCH3), 1.13 (3H, d, / = 6.8, H-6").

3.3.5 MIC90 of HA and analogs for AtolC E. coli
5 ul of an overnight culture of AtolC E. coli were added to 200 \x\ final volume
of fresh LB supplemented with HA or its analogs. The tubes were grown with shaking
for 2 hr at 37°C and the absorbance at 600 nm was measured. The MIC90 is defined as
the lowest concentration of the antibiotic at which 90% of E. coli growth is inhibited
compared to a control E. coli culture grown in the absence of any antibiotic.
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3.3.6 Coupled transcription-translation assay
All coupled transcription-translation experiments were carried out by Daniel
Wilson's group at the Center for Integrated Protein Science, Munich.using an E. coli
lysate-based system for the expression of green fluorescent protein (GFP) in the
presence and absence of antibiotics [98, 99]. GFP was quantitated under native and
denaturing conditions using ImageQuaNT (Molecular Dynamics, Inc.) and represented
graphically using SigmaPlot (Systat Software, Inc.).

3.3.7 Hygromycin sensitivity of Ahyg29 strain
The MIC95 of HA for the Ahyg29 mutant was determined by the agar plate
dilution method as described in section 2.3.13. Briefly, spores were plated on ISP2
agar plates containing varying amounts of HA, incubated at 30°C for 48 hr, and scored
for growth. The MIC95 was defined as the lowest concentration of HA that prevented
visible growth of 95% or more of the colony forming units on the agar plate.

3.4 Results
3.4.1 Sequence analysis of hyg6 and hyg29
The hyg6 gene is comprised of 750 bases. Its predicted protein product
consists of 249 amino acids with a calculated molecular mass of 27.62 kDa, and shows
similarity to the FkbM family of methyltransferases. This protein family is represented
by 31-O-demethyl-FK506 methyltransferase (FkbM) involved in biosynthesis of the
macrocyclic polyketide immunosuppressants FK506 and FK520 [115]. Heterologous
expression and targeted gene disruption had demonstrated that FkbM catalyzed C31
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0-methylation leading to FK506 and FK520. Like FkbM, Hyg6 also does not show
any conserved sequence motifs characteristic of SAM-binding proteins. The hyg29
gene has 1137 bases, and its predicted protein product has 378 amino acids and a
molecular mass of 40.45 kDa. Interestingly, the sequence of Hyg29 shows high
similarity (53 %) to carboxyl 0-methyltransferases of the protein-L-isoaspartate(Daspartate) 0-methyltransferase (PCMT) family. No authentic rRNA methyl
transferases were retrieved in the BLAST search, although a Conserved Domain
Database search also retrieved the KsgA/Dim 1 family of rRNA adenine
dimethyltransferases along with the PCMT family. Conserved SAM-binding motifs
were, however, not identified in Hyg29.

3.4.2 Targeted disruption of hyg6 and hyg29
To determine the roles of hyg6 and hyg29 in HA biosynthesis and selfresistance, the genes were independently replaced with apramycin resistance cassette
in the wild type S. hygroscopicus genome by PCR targeting method [41]. Care was
taken to avoid the regions of overlap of hyg6 and hyg29 with their neighboring genes
(FIGURE 22). The Ahyg6 and Ahyg29 mutant strains thus obtained were cultured
along with the wild type, and the fermentation broths were analyzed by HPLC and
LC-MS for antibiotic production. Analyses of the fermentation broth of Ahyg29
mutant showed that it produced HA, 3, and their corresponding C5"-hydroxyl analogs
2 and 4. The level of HA production had, however, decreased by ~60% (400 mg/1)
compared to that in the wild type (~1 g/1). In contrast, the production of HA was
completely abolished in Ahyg6 strain. Instead, the HPLC trace of this mutant showed a
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dominant new peak at 12.5 min and an additional minor peak at 11.5 min under the
existing HPLC conditions (FIGURE 23).
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FIGURE 22. Arrangement of hyg6 (panel A) and hyg29 (panel B) genes in the
hygromycin A biosynthetic gene cluster. The hyg5 gene in panel A is a mannose
dehydratase homolog while hyg7 is a gene with an unknown function. The hyg27 and
hyg28 genes in panel B are homologous to DAHPS synthase and ABC transporter,
respectively.

The major peak showed a mass in negative mode of m/z = 498 [M - H]~ and the minor
peak showed a mass of m/z = 500 [M - H]\ A mass of 499 is consistent with the mass
of HA that is missing the methylene group bridging 0-4 and 0-5. A mass of 501
corresponds to a C5"-reduced derivative of the major peak. Therefore, the two peaks
are indicative of desmethylene HA analogs (5, 6) (FIGURE 3).
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A. Disruption of hyg29 caused a decrease in hygromycin production whereas
disruption of hyg6 resulted in the production of new metabolites 5 and 6.
B. Mass spectrometric analysis (negative mode) of Ahyg6 fermentation broth. Two
new species were identified with [M-H]~ values of 498 and 500 corresponding to
desmethylenehygromycin A (5) and 5"-dihydrodesmethylenehygromycin A (6),
respectively.
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The amount of production of the major compound was estimated to be approximately
400 mg/L. When the C subunit was provided to this strain, a low amount of HA could
be observed, but the level of 5 was not significantly altered. Thus, the above data
provide evidence that methylation of C5-OH of the aminocyclitol in the biosynthesis
of HA is carried out by the hyg6 gene product.

3.4.3 Structural elucidation of desmethyleneHA analogs
To further characterize the two new compounds isolated from the Ahyg6 strain,
they were purified by semi-preparative HPLC and their structures were elucidated by
NMR. The most compelling data from the ^ - N M R spectra of 5 and 6 was the
absence of either a three-proton singlet at -3.5 ppm (for the 0-5 methyl group of 3), or
two one-proton singlets at -5.18 ppm and 4.83 ppm (for the methylene group bridging
0-4 and 0-5 of HA). Therefore, the MS and ^ - N M R data show that compounds 5
and 6 are nearly identical to HA and 3 except that their aminocyclitol moiety has not
been methylated (FIGURE 24).

The differences in the ^ - N M R spectra between 5 and 6 involve the
fucofuranose moiety. The H-6" signal for 5 is a singlet at 1.99 ppm (overlapping with
protons from a-CH 3 ), while the H-6" signal for 6 is a doublet at 1.20 ppm. The H-4"
signal is also shifted from -4.4 ppm in 5 to 3.74 ppm in 6 (shifts are approximate for
H-4" in 5 because this signal is obscured by other signals at the same chemical shift).
There is also a new signal for 6 that appears at approximately 3.79 ppm, which is
obscured by other signals.
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FIGURE 24. ^ - N M R spectra of hygromycin A (panel A) and
desmethylenehygromycin A (panel B). The methylene bridge protons in hygromycin
A, indicated by arrows in panel A, are absent in desmethylenehygromycin A.
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The upfield shifts for H-4" and H-6" of compound 6 are explained by the fact that
these protons are not adjacent to a carbonyl group, while in 5, these protons are
adjacent to the C-5" ketone. The signal for H-6" for 6 is split into a doublet due to
coupling with a "new" proton at C-5". The new signal at -3.79 ppm (partially
obscured) is due to H-5", which is not present in 5. The H-5" assignment was
confirmed by a COSY experiment, which revealed a crosspeak with H-6". These data
show that compound 6 is the reduced form of compound 5. The compounds were
therefore named desmethylenehygromycin A (5) and 5"-dihydrodesmethylene
hygromycin A (6).

3.4.4 Activity of desmethylenehygromycin A
The antibacterial activity of 5 was determined using AtolC E. coli as test
organism and compared with that of HA, methoxyhygromycin A (3), and 5"dihydroAB (7) to determine the importance of the methyl / methylene group on the
cyclitol. The MIC90 of HA for AtolC E. coli was determined to be 10 p.g/ml.
Compounds 3 and 5 had much less activity, with the MIC90 for both being 150 ug/ml.
Compound 7 lacked inhibitory activity even at a concentration of 250 |ig/ml. Next, the
compounds were assessed for their ability to inhibit the synthesis of green fluorescent
protein (GFP) using an E. coli in vitro coupled transcription-translation system (assays
were conducted in Munich) [98, 99]. HA was shown to be highly active in vitro,
having an IC50 and IC90 of 2.2 |iM and 4.2 |jM, respectively, whereas compound 7 was
inactive (as expected from the MIC values), exhibiting no effect on translation at
100 \iM. In contrast to the poor MIC values for 3 and 5, both compounds displayed
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excellent inhibitory activity in vitro. Based on the IC50 values, 3 was at least as
effective as HA, whereas 5 was ~4-fold more potent (TABLE 4) (FIGURE 25).

TABLE 4. Comparison of MIC90 and IC50/90 data for hygromycin A and analogs
HA
MIC90 (ug/ml)
ICso(uM)
IC9o(uM)

10
2.1
5.2

Hygromycin A (HA)

Methoxyhygromycin A (3)

3

5

150
1.8
6.2

7
>250
>100
>100

150
0.5
1.6

(A)
HA» noDNA

0

0.1

1

3

7.5 [\M]

3 A noDNA

0

1.5

7.5

11 [|iM]

5 a noDNA

0

0.3

2.8

14 fyM]

7 O no DNA 0

1

10

25 [\iM]

Desmethylenehygromycin A (5)

5"-dihydroAB subunit (7)

2

4

6
8 10
Antibiotic [pM]

12

14

FIGURE 25. Effect of hygromycin A and derivatives on in vitro transcriptiontranslation. A. Detection of green fluorescent protein (GFP) using native PAGE and
fluorescence without or with HA, 3, 5, or 7. B. Quantitation of (A) performed in
triplicate with error bars indicating the standard deviation. GFP fluorescence is given
as a percentage where 100% is defined as the fluorescence detected in the absence of
the antibiotic. Assays carried out in Munich by Daniel Wilson's group.
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3.4.5 Resistance of Miyg29 mutant strain to HA
In order to verify if the hyg29 gene contributed to self-resistance of S.
hygroscopicus, spores of the wild type and Ahyg29 strains were grown on agar plates
with different HA concentrations. The MIC95 of HA for the wild type was found to be
400 [ig/ml. The mutant also showed high level of self-resistance, with an MIC95 value
of 300 |ig/ml.

3.5 Discussion
The structure of hygromycin A is uniquely characterized by the presence of a
methylenedioxy bridge. Natural products with a methylenedioxy bridge have been
identified more commonly from plants and less commonly from actinomycetes.
Examples of secondary metabolites from actinomycetes possessing a methylenedioxy
bridge include dioxapyrrolomycin, simaomicin, and the streptovaricins, which have a
six-membered 1,3-dioxine ring [116-118]. FR-900109, the dioxolides, and
pseudoverticin possess a five-membered 1,3-dioxolane ring similar to that seen in HA
[119-121]. In the present study, the gene responsible for the O-methylation step of
methylene bridge formation in HA was identified by gene inactivation experiments.
Two methyltransferase homologs, hyg6 and hyg29, are present in the biosynthetic
gene cluster of HA. Inactivation of hyg6 completely abolished the production of HA
and led to the accumulation of two new products, desmethylenehygromycin A (5) and
its C5"-reduced analog, 5"-dihydrodesmethylenehygromycin A (6), which lacked the
C4-C5 methylenedioxy bridge on the aminocyclitol (FIGURE 3). This work provided
conclusive evidence that the C4-C5 methylene group in HA is contributed by the O-

methylation activity of Hyg6 and not by Hyg29. The desmethylene analogs have not
been detected in the wild type fermentations so far. The MIC data showed that
antibacterial activity of 5 against the AtolC E. coli strain was 15 times less than that of
HA. Interestingly, the MIC value of 5 was the same as that of methoxyhygromycin A
(3), which has a C5-OCH3 group instead of the methylenedioxy bridge. The lower
antibacterial activity of 3 has been reported previously [23, 122]. A study of the
activities of HA analogs modified on the cyclitol and lacking the methylenedioxy ring
has also underlined the significance of this functional group in enhancing the
biological activity of HA [38]. The present data is, thus, in agreement with the existing
information. However, removal of the methylenedioxy ring did not lead to a loss in the
ability to inhibit in vitro protein synthesis. Compound 7, which lacks the C subunit, is
totally inactive, as has been reported in previous studies [34]. In contrast, compounds
3 and 5, where the methylenedioxy ring is absent, retained potent protein synthesis
inhibitory activity, with 5 being ~4 times more active than 3 (TABLE 4) (FIGURE
25). These data suggest that the aminocyclitol ring is indeed essential for translation
inhibition activity, whereas an intact methylenedioxy ring is not. It appears that the
loss in biological activity due to disruption of the methylenedioxy ring stems from
another factor, such as uptake of the drug into the cell, rather than abolishing the
ribosome binding ability of the compound.

The formation of 3 and 5 suggests that the enzyme catalyzing the amide bond
formation that connects the AB- and C- fragments has relaxed substrate specificity and
is able to recognize the unmethylated (C5-OH) aminocyclitol, the C5-OCH3
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aminocyclitol, and also the C4-C5 methylenedioxy-bridged aminocyclitol as substrates
(FIGURE 26). As suggested in an earlier report, the cyclization step of methylene
dioxy bridge formation cannot occur once the aminocyclitol gets attached to the AB
subunit, and so 3 represents a byproduct and not a precursor of HA [40]. The exact
placement of Hyg6-catalyzed C5-0-methylation in the pathway sequence still could
not be determined. The order of the biosynthetic steps leading from glucosesphosphate to myoinositol is conserved across other aminocyclitol antibiotics such as
streptomycin, bluensomycin, spectinomycin, and diverges only from the steps
subsequent to myoinositol formation [123]. As has already been stated, 5 has not been
detected in the wild type fermentation. Compound 5 has also not been found in a
Ahyg7 mutant that was blocked in the cyclization step of methylenedioxy bridge
formation, and so, produced only 3 (data unpublished). These observations may imply
that, under physiological conditions, methylation happens only on free neo-inosamine
2 before its attachment to the AB subunit. This means that 5 is not a precursor of 3,
and that formation of 5 is facilitated due to the relaxed substrate specificity of the
amide bridge-forming enzyme only when the normal progression of the pathway is
blocked, as in the Ahyg6 mutant. An alternate explanation could also be that the C5-0methylation must be taking place at a much faster rate than amide bond formation.
However, failure to detect even trace levels of 5 in wild type fermentation lends more
support to the former possibility than to the latter.
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FIGURE 26. Routes for biosynthesis of desmethylenehygromycin A and
methoxyhygromycin A during the course of HA biosynthesis
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Inactivation of the second methyltransferase homolog, hyg29, resulted in a
decrease in the yield of HA, although the antibiotic production profile and selfresistance were not affected. The present study did not provide any information that
would support the proposed role of hyg29 as an rRNA methylase-encoding gene. At
the time of this study, it was not known whether the ribosomes of S. hygroscopicus are
resistant to HA or not. Moreover, ribosomal self-resistance is not always observed for
ribosome-targeting antibiotics. If the hyg29 gene product is indeed an rRNA
methylase, the high level of HA resistance of the Ahyg29 mutant suggests that in the
absence of target-site modification by hyg29, self-resistance is possibly being
conferred by the other resistance determinants in the HA gene cluster, namely the
putative efflux pumps and the HA inactivating ^-phosphotransferase. It will be
interesting to study if a difference in rRNA methylation and HA-binding patterns
exists between the ribosomes extracted from the wild type and the Ahyg29 strain.

In summary, the present study has unambiguously identified hyg6 as the
methyltransferase gene responsible for the C5-0-methylation step of HA biosynthesis
and has also led to the isolation of two previously unidentified HA analogs. The
function of the other methyltransferase gene, hyg29, remains presently unresolved and
can only be verified by more specific studies such as in vitro rRNA methylation
assays.
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4. Involvement of a short chain dehydrogenase, a putative ABC transporter, and
a putative proton-gradient dependent transporter in the biosynthesis and efflux
of hygromycin A

4.1 Summary
The hygl9 and hyg28 genes in the biosynthetic gene cluster of hygromycin A
(HA) putatively encode a proton gradient-dependent transporter and an ATP-binding
cassette (ABC) transporter, respectively, and either or both the gene products are
hypothesized to confer intrinsic HA resistance to the producer strain, S. hygroscopicus
NRRL 2388, by antibiotic efflux. A Ahyg28 mutant, resulting from disruption of the
ABC transporter gene, produced the same amount of HA as the wild type and also
demonstrated similar levels of self-resistance. On the other hand, a Ahygl9 mutant,
generated by disrupting the proton gradient-dependent transporter gene, produced
lesser amounts of HA and accumulated 5"-dihydrohygromycin A, but showed no
decrease in self-resistance due to loss of hygl9. Interestingly, a strain in which hygl9
was disrupted together with hyg21 (^-phosphotransferase gene) was significantly
more sensitive to HA. This observation indicated that HA self-resistance in the
producer strain arises by synergistic functioning of multiple gene products.
Accumulation of 5"-dihydrohygromycin A in Ahygl9 also suggested that this
compound is the immediate precursor of HA in the biosynthetic sequence, and further
indicated that the dehydrogenation of 5"-dihydrohygromycin A to HA is coupled to
efficient HA efflux. A short chain dehydrogenase encoded by hyg26 was expressed
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and purified from E. coli, and was shown to reversibly catalyze the above reaction
using NAD(H) as cofactor.

4.2 Introduction
The antibiotic efflux system, comprised of membrane transporter proteins, is
considered to have evolved in antibiotic producers primarily for effective secretion of
the completely synthesized metabolite. It contributes to intrinsic resistance by keeping
the intracellular drug concentrations at subtoxic levels and by excreting any drug
molecules that re-enter the cell after initial export [42]. Both primary active
transporters, which couple molecular transport to ATP hydrolysis, and secondary
active transporters, which use the energy of the membrane electrochemical gradient
for efflux, occur in antibiotic producers.

The ATP hydrolysis-dependent transporters belong to the ATP-binding
cassette (ABC) transporter superfamily. This is one of the largest families of
transporter proteins, with members occurring ubiquitously in all phyla of organisms
from prokaryotes to humans [124-126]. These proteins bring about transport of a wide
variety of substrates that includes small molecules like sugars, amino acids,
antibiotics, as well as macromolecules like proteins and polysaccharides. Structurally,
they are comprised of two hydrophilic ATP-binding domains and two hydrophobic
transmembrane domains, which may be present on the same protein or on different
polypeptides [76]. A two-site model has been proposed for transport by ABC proteins,
according to which the transmembrane domains possess an intracellular high-affinity
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drug binding site and an extracellular low affinity site, and ATP hydrolysis induces
conformational changes that interconvert these sites, resulting in efflux of the drug
[127]. As described in section 1.3.3, the ABC transporters in antibiotic-producing
actinomycetes have been classified into three groups [77]. The Type I transporter
system comprises two genes, one of which encodes a protein with a single ATP
binding domain, and the second gene present immediately downstream encodes a
membrane protein with six transmembrane segments. Type I ABC transporters have
been identified in daunorubicin, tetronasin, mithramycin, and oleandomycin producers
[78-81]. The Type II group is comprised of a single gene that encodes a protein with
two ATP binding domains; a gene for the membrane component has not been
identified in the corresponding biosynthetic gene cluster. Transporters of this type
occur in carbomycin, tylosin, oleandomycin, A201A, and lincomycin producers [8286]. The type III system is made of a single gene that encodes a protein with one ATP
binding domain and one transmembrane domain. This type has been reported from the
bleomycin and streptomycin producers [87, 88].

The electrochemical gradient-dependent transporters involved in antibiotic
efflux in actinomycetes typically belong to the major facilitator superfamily (MFS).
These proteins bring about transport of only small molecules, and together with the
ABC transporters, form nearly 50% of all transporter proteins [73, 124-126, 128]. The
MFS transporters for drug efflux are chiefly proton-gradient dependent antiporters
composed of a single polypeptide with either 14 transmembrane segments (drug:H+
antiporter, 14 spanner (DHA14) family), or 12 transmembrane segments (drug:H+
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antiporter, 12 spanner (DHA12) family). Members of DHA14 family have been
identified in producers of tetracenomycin, puromycin, cephamycin, and mitomycin C
[74, 129-131]. MFS transporters with 12 membrane-spanning domains have been
reported from producers of lincomycin and valanimycin [132, 133]. The N-termini of
MFS proteins are more conserved and are thought to be involved in transport, while
the C-termini are more variable in sequence for specificity of ligand recognition [73,
128].

The majority of these efflux pumps are specific for the antibiotic with which
they are associated in the biosynthetic gene cluster, but transporters from antibiotic
producers that confer multidrug resistance phenotype are also known, as in the case of
pristinamycin producer [134]. The expression of genes encoding transporter proteins is
often tightly linked to one or more genes present in the biosynthetic gene cluster of the
corresponding antibiotic and can also be induced by biosynthetic pathway
intermediates / antibiotic precursors. This was reported for actinorhodin export in S.
coelicolor A3(2), in which it was observed that expression of actA, the gene for the
transmembrane pump in the actinorhodin biosynthetic gene cluster, is regulated by a
repressor protein encoded by actR in the gene cluster, and that the repression is
relieved by an antibiotically inactive precursor of actinorhodin [135]. This
phenomenon, referred to as a 'feed-forward' mechanism for activation of antibiotic
export, ensures that the transporter is made available as soon as the final biosynthetic
product is generated and needs to be removed from inside the cell.
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As mentioned in chapter 1, there are two putative HA efflux/resistance genes,
hygl9 and hyg28, in the HA biosynthetic gene cluster. In the study reported in this
chapter, the proposed roles of these two genes and their functional association with the
hyg26 gene that encodes a short chain dehydrogenase have been investigated.
Disruption of hyg28, which encodes a putative ABC transporter, revealed that this
gene is not essential for HA export. Disruption of hygl9, which encodes a putative
proton gradient-dependent transporter, reduced HA production and also caused
accumulation of its reduced analog, 5"-dihydrohygromycin A. This observation
suggested that HA biosynthesis is associated with Hygl9-dependent efflux. Studies on
hyg26 showed that the enzyme encoded by it is a NAD-dependent dehydrogenase with
reversible activity, and further indicated that the conversion of 5"-dihydrohygromycin
A to HA, catalyzed by Hyg26, is the final step of HA biosynthesis prior to efflux.

4.3 Materials and methods
4.3.1 Chemicals, bacterial strains, and growth conditions
All antibiotics and chemicals were purchased from Sigma Aldrich. PCR
primers were obtained from Integrated DNA Technologies. Enzymes for DNA
manipulations were obtained from New England Biolabs. Hygromycin A (HA) was
kindly provided by Pfizer Inc. Dihydrohygromycin A (2), 5"-dihydromethoxy
hygromycin A (4), and (£)-3-(3-hydroxy-4-(9-a-fucofuranosylphenyl)-2-methylacrylic
acid (dihydroAB subunit) (7) were purified from fermentation broth of the S.
hygroscopicus SCH30 mutant strain by semi-preparative HPLC method as described
earlier [40]. A hyg7 (D-aminoacylase homolog) disruption strain of S. hygroscopicus
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was the source for methoxyhygromycin A (3) (data unpublished), and the hyg6 (C5 Omethyltransferase) disruption strain was the source for desmethylenehygromycin A (5)
and 5"-dihydrodesmethylenehygromycin A (6) (chapter 3). S. hygroscopicus strains
were propagated as described earlier [39, 40]. E. coli strains were cultured using
standard protocols [136]. The AtolC E. coli strain was procured from the E. coli
Genetic Stock Center at Yale University.

4.3.2 Nucleotide and protein sequence analysis
Homology searches for sequences of hygl9, hyg26, and hyg28 genes were
carried out using the BLAST suite of programs at the National Center for
Biotechnology Information website [96]. Protein motif searches were carried out using
the PROSITE database [97]. Hydropathy analysis for Hygl9 was based on the amino
acid hydropathy values of Kyte and Doolittle, and carried out at the Transporter
Classification Database server [137, 138]. The MEMSAT3 program was also used for
secondary structure and topology prediction of Hygl9 [139].

4.3.3 Gene disruption experiments
The hygl9 and hyg28 genes, and also a segment of the HA biosynthetic gene
cluster comprised of hygl9, hyg20, and hyg21 genes, were individually replaced by
apramycin resistance cassette using the PCR targeted Streptomyces gene replacement
method [41]. The primers used to amplify the disruption cassette from pD773 plasmid
are listed in TABLE 5. Primers for hyg28 disruption were designed such that the 68nucleotide overlap between the 3'-end of hyg28 and the 5'-end of the downstream
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hyg29 gene was unaffected. The hygl9 and hygl9+hyg20+hyg21 disruptions were
carried out in cosmid 17E3, while hyg28 gene disruption was done in cosmid 15A10
[40]. The recombinant cosmids were introduced into S. hygroscopicus wild type by
conjugation and selected for apramycin resistance. The genotype of the mutant strains
was confirmed by PCR amplification of apramycin cassette from chromosomal DNA
and by verifying the sequence of the PCR product. Automated DNA sequencing was
done at the MMI research core facility at Oregon Health and Science University. The
DNA sequence data were analyzed using Accelrys DS Gene software.
TABLE 5; Primers used for disruption o(hyg!9 and hyg28
Primers for hyg!9 gene disruption
/ryg;9_KO_Forw
GATCCGACCCGTGCCGGGCGGAAGGGAGCACCAGTGATGA7TC
CGGGGATCCGTCGA CC
hygl9_KO_Revi
GGTGATGAGCGGGGCGCTGAGCCAGAGGAACATCACGACrcTA
GGCTGGAGCTGCTTC
Outer primers for verification othyg!9 gene disruption
hyg 79_Out_Forw
ATGAAGTCGCCACCCGAGC
fryg79_Out_Revr
GTCGGCGAAGTGGTCCAGGC
Primers for hyg28 gene disruption
Ay*2S_KO_Forw
CTGATGACTGCCACTCTCGTCGCCAAGGATCTGGCCGCG47TCC
GGGGATCCGTCGACC
hyg28_KO_FoTw
CTCGGTGACCCGGCCGTCCGCCACCTCCAGGCGGCGGGTTG7V1
GGCTGGAGCTGCTTC
Outer primers for verification of hyg28 gene disruption
/ivg2S_Out_Forw
CTCAATCGGGCGCAGGCC
fry,?2<g_Out_Revr TGGACAGAGGCCGGACGG
Primers for (hygl9+hyg20+hyg21) gene disruption
Forward
GATCCGACCCGTGCCGGGCGGAAGGGAGCACCAGTGATG47TC
CGGGGATCCGTCGACC
Reverse
ACCGTTGACCGAGAATGGGTAAAGGAGCAGAAAACAATGrGrA
GGCTGGAGCTGCTTC
Outer primers for verification of (hyg!9+hyg20+hyg21) gene disruption
Outer_Forw
ATGAAGTCGCCACCCGAGC
Outer_Revr
CATGCGCACCTGGCTGAC
Expression primers for hyg26 gene encoding short chain dehydrogenase
Forward
CATATGAGTGGACTGATGCGGGAC
Reverse

GGATCCTCAGAATTCGCTGACGC

The 39-nucleotide homologous region flanking the targeted gene is indicated in bold. The italicized
primer region is homologous to pD773. The Ndel and BamHl sites in hyg26 expression primers are
indicated in bold.
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4.3.4 Analysis of antibiotic production in S. hygroscopicus strains
Fermentation broths of S. hygroscopicus disruption strains were analyzed for
antibiotic production by high performance liquid chromatography (HPLC) and liquid
chromatography - mass spectrometry (LC-MS) methods on a Bruker Daltonics
MicroTOF-Q instrument fitted with Agilent 1100 series HPLC system. Cell-free
extracts were generated by methanol lysis of mycelia and examined by HPLC [140].
The production yields of HA and related metabolites were estimated from their
corresponding peak areas in the chromatograms using a standard curve of HA as
reference.

4.3.5 Sensitivity of 5. hygroscopicus strains to hygromycin A
HA sensitivity of S. hygroscopicus wild type and mutant strains was
determined by agar plate dilution method as described previously [140]. Briefly,
spores were plated on ISP2 agar plates containing varying amounts of HA, incubated
at 30 °C for 48 hr, and scored for growth. The MIC95 was defined as the lowest
concentration of HA that prevented visible growth of 95% or more of the colony
forming units on the agar plate.

4.3.6 Bioactivity of 5"-dihydrohygromycin A and other dihydro analogs
The AtolC E. coli strain was used as test organism to determine the antibiotic
activity of 2, 4, 6, and 7. The strain was grown in 200 ul LB at 37 °C for 2 hr in the
presence of different concentrations of antibiotic, and the A600 was measured. The
MIC90 was defined as the lowest concentration of the antibiotic at which 90% of
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bacterial growth was inhibited compared to a control E. coli culture grown in the
absence of any antibiotic.

4.3.7 Coupled transcription-translation assay
All coupled transcription-translation experiments were performed using an
E. coli lysate-based system in the presence and absence of antibiotics as described in
chapters 2 and 3 [98, 99]. Native and SDS gels were quantitated using ImageQuaNT
(Molecular Dynamics, Inc.) and represented graphically using SigmaPlot (Systat
Software, Inc.).

4.3.8 Cloning, overexpression, and purification of recombinant Hyg26
The 816-bp hyg26 gene was amplified from cosmid 17E3. Primers were
designed to introduce an Ndel restriction site at the initiation codon and a BamHI
restriction site 3' to the termination codon (TABLE 5). Amplification was performed
using the following temperature program: initial denaturation at 95 °C for 5 min, 25
cycles of amplification (45 s denaturation at 95 °C, 45 s primer annealing at 56 °C, 1
min extension at 72 °C), and a final 7 min extension at 72 °C. The gene was
subsequently cloned into the Ndel and BamHI restriction sites of pET15b vector
(Novagen). The resulting pET15b-/ryg26 construct was introduced into E. coli BL21CodonPlus (DE3) expression host (Stratagene) by transformation. For protein
expression, cells were grown at 37 °C in LB medium containing 100 p.g/ml ampicillin
and 50 ug/ml chloramphenicol. When an A6oo of 0.6 was reached, the culture flask
was brought to room temperature (-23 °C), and expression was induced by adding 0.5
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mM isopropyl thio-P-D-galactoside (IPTG). After further 6 hr incubation, cells were
harvested by centrifugation and stored at -80 °C.

The N-terminal His-tagged Hyg26 was purified under native conditions
according to Qiagen's Ni-NTA protocol. Cells were resuspended in BugBuster Master
Mix protein extraction reagent (Novagen) and lysed by incubating at room
temperature for 30 min. The lysate was cleared by centrifugation and the supernatant
was loaded onto Ni-NTA agarose prequilibrated with buffer containing 50 mM
NaH 2 P0 4 , 300 mM NaCl, and 10 mM imidazole [pH 8.0]. The column was washed
with wash buffer (50 mM NaH 2 P0 4 , 300 mM NaCl, 20 mM imidazole [pH 8.0]) and
the protein was eluted with elution buffer (50 mM NaH 2 P0 4 , 300 mM NaCl, 250 mM
imidazole [pH 8.0]). The eluted protein was dialyzed overnight against a buffer
containing 50 mM Tris-HCl (pH 7.5), 20% glycerol, and 5 mM 2-mercaptoethanol,
and stored at -80 °C until further use.

4.3.9 Determination of molecular mass of Hyg26
The molecular mass of purified His-tagged Hyg26 was determined by sizeexclusion chromatography using a Phenomenex BioSep-SEC-S4000 size exclusion
column fitted to an Agilent 1100 series HPLC system. The column was equilibrated
and eluted with 20 mM sodium phosphate (pH 7.2) at a flow rate of 0.5 ml/min.
Carbonic anhydrase (25 kDa), bovine serum albumin (66 kDa), P-amylase (200 kDa),
apoferritin (443 kDa), and thyroglobulin (669 kDa) were used as standards. The void
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and total column volumes were calculated from the elution volumes of blue dextran
(2000 kDa) and 2,4-dinitrophenyl aspartate (299 Da), respectively.

4.3.10 Hyg26 enzyme assays and kinetic analyses
Initial enzyme assays were performed at 30 °C with 4 jag of purified enzyme in
a 100 (il reaction mixture of 50 mM Tris-HCl (pH 7.5) and 2 mM tris(2-carboxyethyl)
phosphine (TCEP). The dehydrogenase activity was studied by incubating Hyg26 with
100 uM of the 5"-dihydro analogs 2, 4, 6, or 7, and 1000 pM NAD or NADP. For
lactate dehydrogenase coupled assays, 1000 p.M sodium pyruvate and 5 units of
lactate dehydrogenase were added. The reductase activity was detected using 100 uM
HA, 3, or 5, and 1000 pM NADH or NADPH. After incubation for 2 hr at 30 °C, the
sample was loaded onto a reverse-phase HPLC column (Agilent Eclipse XDB-C18) to
detect the oxidized products (with longer retention times) in the dehydrogenase assay
or the reduced products (with shorter retention times) in case of the reductase assay.
Samples were separated at a flow rate of 1 ml/min with a methanol:water gradient as
described earlier [140]. The optimal temperature and pH for Hyg26 reductase activity
were determined with 100 uM HA and 1000 pM NADH in a 15 min assay followed
by quantitating the amount of product (2) formed from its peak area. The temperatures
used were 23 °C (room temperature), 30 °C, 37 °C, and 42 °C. For pH studies the
following buffers were used: 50 mM potassium acetate, pH 4.0, 5.0; 50 mM potassium
phosphate, pH 6.0, 7.0; 50 mM Tris-HCl, pH 7.5, 8.0, and 9.0. The metal requirement
was similarly checked by conducting the assay in the presence of 5 mM and 10 mM
ethylenediamine-tetraacetic acid (EDTA). Kinetic analyses of reductase activity were
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carried out at 37°C for 15 min with 800 ng Hyg26 in 100 (al assay buffer comprised of
50 mM phosphate (pH 6) and 2 mM TCEP. The NADH concentration was fixed at 60
mM while the antibiotic concentration was varied from 2 mM upto 60 mM where
needed. For kinetic studies of NADH, HA was fixed at 20 mM while NADH was
varied from 0.25 mM to 10 mM. Each assay was performed in duplicate and the
average values of the two measurements were plotted in GraFit 4 to determine the
kinetic parameters.

4.4 Results
4.4.1 Predicted roles of hygl9 and hyg28 genes in the HA biosynthetic gene
cluster
The biosynthetic gene cluster of hygromycin A has two genes, hygl9 and
hyg28, that encode putative transporter proteins. The predicted translation product of
hygl9 has 416 amino acids with a theoretical molecular mass of 43.85 kDa. A search
of the NCBI protein sequence database using the deduced Hygl9 sequence returns
several transmembrane proteins belonging to the major facilitator superfamily (MFS).
The highest sequence similarity (66%) is observed with a putative transmembrane
protein, Ata9, from the biosynthetic gene cluster of A201A antibiotic from
Saccharothrix mutabilis subsp. capreolus. The structure of HA resembles that of
A201A in the A and B subunits, and many genes with similar sequences, and possibly
similar functions, have been identified in the biosynthetic gene clusters of these two
antibiotics [40]. The N-terminal region of Hygl9 specifically shows similarity to MFS
proteins involved in drug efflux, such as the tetracycline resistance determinant TetV
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from Mycobacterium smegmatis, macrolide efflux protein MefA from Streptococcus
pneumoniae, and chloramphenicol resistance protein from Streptomyces lividans.
Hydropathy analysis and transmembrane topology prediction suggest that Hygl9 has
12 transmembrane (TM) helices with cytoplasmic N- and C-termini, and thus is a
member of the proton gradient-dependent DHA12 family of MFS transporters. Five
sequence motifs have been identified in the DHA12 efflux proteins [72]. Hygl9 does
not exhibit full conservation of all the motifs but a partially conserved motif C
(gxxxGPxxGGrl) in TM5 (positions 163-181) and a partially conserved motif G
(GxxxGPL) in TM11 (positions 373 - 392) can be clearly distinguished. Based on
these observations, Hygl9 is hypothesized to be a proton gradient-dependent efflux
protein that confers resistance to S. hygroscopicus by exporting HA out of the cell.

The deduced translation product of hyg28, with 570 residues and a theoretical
molecular mass of 61.47 kDa, shows homology to several ATP binding cassette
(ABC) type transporter proteins, including Ardl from the A201A gene cluster that is
known to confer resistance to A201A in S. lividans [85]. Two ABC domains
containing the Walker A and Walker B motifs characteristic of ATPases are present in
Hyg28. The Walker A motif ([AG]-x(4)-G-K-[ST]) is a glycine-rich loop that binds to
the phosphates of ATP or GTP [102]. The Walker B motif (hhhhDEPT, where h
indicates a hydrophobic residue) coordinates a magnesium ion [102]. Therefore, the
hyg28 gene is predicted to encode a type II ABC transporter protein, which in
association with an unidentified membrane component, constitutes the second
transporter system for HA efflux and subsequent self-resistance.
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4.4.2 Effect of hygl9 and hyg28 gene disruptions on HA biosynthesis and efflux
In order to determine whether Hygl9 and Hyg28 are involved in antibiotic
biosynthesis and efflux, the corresponding genes were individually replaced with
apramycin resistance cassette in the S. hygroscopicus wild type (FIGURE 27). The
resulting mutant strains, Ahygl9 and Ahyg28, were cultured, the mycelia were
removed by centrifugation, and the filtered supernatants were analyzed by HPLC and
LC-MS for antibiotic production. Analysis of fermentation broth of the Ahyg28
mutant revealed that the antibiotic production profile was unaffected by hyg28
disruption. The strain produced nearly the same amount (-1.5 gm/1) of HA as the wild
type (data not shown). This clearly indicates that Hyg28 is not essential for antibiotic
biosynthesis and efflux. On the other hand, disruption of hygl9 caused HA production
to drop to -509 mg/1, a three-fold decrease compared to the HA yield in the wild type.
The levels of methoxyhygromycin A (3) and 5"-dihydromethoxyhygromycin A (4)
also appeared to be similarly reduced. Interestingly, the yield of 5"-dihydro
hygromycin A (2) in Ahygl9 increased significantly to -380 mg/1 from -37 mg/1 seen
in the wild type (FIGURE 28). A slight increase in the amount of 5"-dihydroAB (7)
was also observed in Ahygl9, which was detected only in trace levels in the wild type,
(see FIGURE 3 for structures of compounds).
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FIGURE 27. Arrangement oihygl9 (panel A) and hyg28 (panel B) in the
hygromycin A biosynthetic gene cluster. The hygl8 gene in panel A is a myoinositol-1-phosphate synthase homolog while hyg20 is a transglucosylase homolog.
The hyg27 and hyg29 genes in panel B are homologous to DAHP synthase and
methyltransferase, respectively.
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FIGURE 28. Reverse-phase HPLC analysis of fermentation broths of wild type
(panel A) and \hygl9 mutant (panel B). Reduced HA production and accumulation
of 5"-dihydrohygromycin A were observed in Ahygl9.

It was speculated that the reduced amount of HA in the fermentation broth of
Ahygl9 could be a consequence of intracellular HA accumulation due to impaired
transmembrane transport. To test this possibility, the mycelium of Ahygl9 was lysed
by methanol treatment and the lyaste was analyzed by HPLC. The cell lysates of the
wild type and Ahyg28 were also examined alongside in the same way. However, HA
and related metabolites, including any phosphorylated forms, were not detected in
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the cell lysates of any of the strains. These data demonstrate that all detectable HA and
related products are outside the cell and that they are exported in the absence of
Hygl9.

4.4.3 Contribution of hygl9 and hyg28 gene products to self-resistance of S.
hygroscopicus
The wild type and mutant strains were assessed for their sensitivity to HA by
growing their spores on agar plates with different antibiotic concentrations. The MIC95
of HA for the wild type was found to be 400 ug/ml. The mutants also showed high
levels of resistance, with MIC95 values of 400 ug/ml and 300 ug/ml for Ahygl9 and
A.hyg28, respectively. These data indicate that the self-resistance of S. hygroscopicus
is not entirely conferred by hygl9 or hyg28. Another mutant strain was generated by
disrupting hygl9 together with the hyg20 and hyg21 genes present immediately
downstream to it (FIGURE 29). The hyg20 gene encodes a putative transglucosylase/
mutase for generating the A subunit and its disruption was observed to abolish
antibiotic production completely (unpublished data). The hyg21 encodes an antibioticmodifying 0-phosphotransferase with a probable role in self-resistance, and loss of
this gene results in reduced HA production (chapter 2) [140]. The
A(hygl9+hyg20+hyg21) strain did not produce HA and showed significantly increased
sensitivity with a MIC95 of 75 ug/ml. A Ahyg20 strain, in which the above mentioned
putative transglucosylase/mutase gene alone was disrupted, had a MIC95 of 300 ug/ml,
which is not significantly lower than that of the wild type. The MIC95 of S. lividans for
HA was determined to be 20 ug/ml. These data suggest that the increased sensitivity
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of A(hygl9+hyg20+hyg21) is due to the loss of hygl9 and hyg21, implying a
synergistic role of these two genes in self-resistance.

61 bp

6bp

74 bp

266 bp

FIGURE 29. Schematic representation of replacement of hygl9, hyg20, and
hyg21 genes with the apramycin resistance cassette

4.4.4 Biological activity of C5"-dihydro analogs
Compounds 2, 4, and 6 are the C5"-dihydro analogs of HA,
methoxyhygromycin A (3), and desmethylenehygromycin A (5), respectively
(FIGURE 3). They were studied for their ability to inhibit growth of AtolC E. coli, and
also for their ability to inhibit protein synthesis in an E. coli in vitro coupled
transcription-translation system [98, 99]. The MIC90 values of 2, 4, and 6 were
determined to be 20 ug/ml, 150 |ag/ml, and 150 |ig/ml respectively (TABLE 6). These
values are similar to the MIC of the corresponding 5"-oxidized analogs (TABLE 4,
chapter 3). The 5"-dihydroAB subunit (7) was inactive against AtolC E. coli even at
250 |ig/ml. In the in vitro protein synthesis inhibition assay, however, the IC50 and
IC90 values indicated that 2 was 4-7 times more active than HA. Compounds 4 and 6
were less potent protein synthesis inhibitors compared to their oxidized forms 3 and 5,
where as 7 had no activity even at 100 p.M (TABLE 6, FIGURE 30).
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TABLE 6. Comparison of MIC90 and IC50/90 data for 5"-dihydrohygromycin
analogs

MIC90 (ug/ml)
IC50 (uM)
IC90 (uM)

HA
10

2
20

2.1
5.2

0.3
1.5

3
150
1.8
6.2

4
150
7.4
50

5
150
0.5
1.6

6
150
2.7
14.1

5"-dihydrohygromycin A (2)

5"-dihydromethoxyhygromycin A (4)

5"-dihydrodesmethylenehygromycin A (6)

20
30
40
Antibiotic [pMJ

FIGURE 30. Effect of 5"-dihydro derivatives on in vitro synthesis of green
fluorescent protein (GFP). GFP fluorescence is given as a percentage where 100% is
defined as the fluorescence detected in the absence of the antibiotic. Activities of HA,
3, and 5 are reproduced from TABLE 4. Assays were carried out in Munich by Daniel
Wilson's group.

4.4.5 Enzymatic characterization of a short chain dehydrogenase encoded by
hyg26
A gene disruption study had unequivocally demonstrated that a short chain
dehydrogenase/reductase encoded by the hyg26 gene is responsible for the C5
dehydrogenation of L-fucofuranose [40]. It was suggested, but not proved, that this
biosynthetic step precedes the glycosyltransferase reaction that connects the A subunit
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to the B subunit. Enhanced production of 2 in Ahygl9 suggests a contrary hypothesis
that dehydrogenation of 2 to form HA might be the last step of HA biosynthesis.
Compound 2 would, therefore, represent a pathway intermediate and not a shunt
metabolite. It was reasoned that if efflux of HA is compromised in the Ahygl9 mutant,
it would result in longer intracellular HA retention and an inhibitory effect either on
the expression of hyg26 or on the activity of the enzyme, resulting in accumulation of
2. The presence of HA and 2 only in the fermentation broth would imply the existence
of other systems capable of export of these antibiotics. In order to verify this
hypothesis in vitro, a pET15b-/z_yg26" expression vector was constructed and the
enzyme was assayed to determine its ability to interconvert HA and 2. The N-terminal
hexahistidine tagged Hyg26 was purified by Ni2+ affinity chromatography and showed
the expected size of ~30 kDa on SDS PAGE (FIGURE 31). The apparent molecular
mass of native recombinant Hyg26 was determined by size-exclusion chromatography
to be approximately 64000 Da, suggesting that recombinant Hyg26 is a dimeric
protein (FIGURE 32).
M

El

E2

E3

E4

37 kDa
25 kDa

.N'-His tagged Hyg26
(~ 30 kDa)

FIGURE 31. SDS PAGE analysis of Ni-NTA purified Hyg26.
M - Standard protein marker; El - E4 - Hyg26 elution fractions
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FIGURE 32. Molecular weight estimation for recombinant Hyg26 by size
exclusion chromatography. Thyreoglobulin (669 kDa), apoferritin (443 kDa), 0amylase (200 kDa), bovine serum albumin (66 kDa), and carbonic anhydrase (25 kDa)
were used as standards.

The dehydrogenase activity of the enzyme was assayed by incubating it with 2,
4, or 6 in the presence of NAD+ or NADP+ as cofactor. Reverse-phase HPLC analysis
of each reaction mixture provided with NAD+ showed the appearance of a new peak
with longer retention time than the substrate (FIGURE 33 for assay with 2). This peak
was not observed in a control without Hyg26 or in the assay with NADP+. The
retention time of the new peak coincided with that of the corresponding C5"-oxidized
analog (HA, 3, and 5), and therefore, represents the product of Hyg26-dependent
dehydrogenation. The very low product formation (1.2 - 1.5 |jM from 100 (iM of
substrate after 2 hr at 30 °C) may reflect Hyg26 inhibition either by the oxidized
antibiotic or by the resulting NADH. The oxidized antibiotic could not be removed
from the reaction mixture, but coupled enzymatic assays that would regenerate NAD+
were performed using pyruvate and lactate dehydrogenase. However, no increase in
product amount was observed even after overnight incubations under these conditions.
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FIGURE 33. Reverse-phase HPLC analysis of 5"-dihydrohygromycin A (2)
dehydrogenation by Hyg26. (A) Control reaction of 2 and NAD without Hyg26. (B)
Reaction of 5"-dihydrohygromycin A (2) and NAD after incubation with Hyg26
showing formation of HA.

The ability of Hyg26 to catalyze the reverse reaction (reductase activity) was
also investigated. Assays were carried out with HA, 3, or 5 in the presence of NADH
or NADPH, followed by HPLC analyses. Compared to a control without Hyg26, each
of the NADH assays showed a significant decrease in the amount of substrate and the
appearance of a new peak with shorter retention time than the substrate (FIGURE 34).
This peak was not observed in the reaction with NADPH. Mass spectrometric analyses
of the NADH reaction mixtures showed that the compounds under the new peaks had
an increase in mass by 2 AMU with respect to the substrates, consistent with that
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expected for the C5"-reduced analogs. These observations confirm that Hyg26 is an
NAD+/NADH-dependent oxidoreductase with broad substrate specificity. These data
demonstrated that under the given assay conditions, the enzyme catalyzed the reverse
reaction more efficiently than the forward biosynthetic reaction, suggesting that the
equilibrium position favors the reduced product.
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FIGURE 34. HPLC analysis of hygromycin A (HA) reduction by Hyg26. (A)
Control reaction of HA and NADH without Hyg26. (B) Reaction of HA and NADH
after incubation with Hyg26, showing formation of 5"-dihydrohygromycin A (2).

The optimal pH for catalysis of the reverse reaction was determined within a
4.0 - 9.0 pH range and was found to be 6.0 (FIGURE 35A). The optimal temperature
was 37 °C among temperatures from 23 °C to 42 °C, although no significant
difference was observed between the amounts of product formed at 30 °C and 37 °C
(FIGURE 35B). The metal-chelating reagent EDTA did not reduce enzyme activity,
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suggesting that, like other short chain dehydrogenases, Hyg26 is metal ionindependent (data not shown) [141].

FIGURE 35A. pH dependence of Hyg26 reductase
activity. Assays were done with 100 uM HA and
1000 uM NADH at 37°C for 30 min and the amount
of 5"-dihydrohygromycin A was determined.

35
Temperature (C)
FIGURE 35B. Temperature dependence of
Hyg26 reductase activity. Assays were done with
100 uM HA and 1000 uM NADH at pH 7.5 for 30
min and the amount of 5"-dihydrohygromycin A
was determined.

Analysis of the steady state kinetic parameters for reduction of HA, 3, and 5 showed
that Hyg26 has very low affinity for them as indicated by the high Km values (in
millimolar range, TABLE 7, FIGURE 36). The catalytic efficiency, as indicated by
kcat/Km, was found to be comparable for all three substrates. The Km for NADH was
determined to be 399.5 ± 33.7 |aM.

TABLE 7. Kinetic parameters for Hyg26 reductase activity
Substrate
Hygromycin (HA)
Methoxyhygromycin A (3)
Desmethylenehygromycin A (5)

K

Kcat'-l^m

cat
1

(a" )
5.1
15.5
31.7

(mM)
5.8 ±0.8
19.8 ±1.9
63.6 + 24.4

(M"1 s"1)
1.0x10'
0.9 x 103
0.9 x 103
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FIGURE 36. Kinetic analysis of Hyg26 reductase activity using HA, 3, or 5, and
NADH

4.5 Discussion
Sequence analysis of the biosynthetic gene cluster of hygromycin A showed
that the hygl9 gene encodes a putative proton gradient-dependent transmembrane
protein and the hyg28 gene encodes a putative type II ABC transporter, and either one
or both of these were hypothesized to be involved in HA efflux and self-resistance.
The antibiotic production profile and intrinsic resistance of the Ahyg28 strain were
similar to that of the wild type, which revealed that hyg28 is not essential for HA
efflux and resistance of S. hygroscopicus. Disruption of hygl9 also did not affect
resistance, although there were qualitative changes in antibiotic production. Similar
observations with regard to resistance have been made in the landomycin E producer
S. globisporus 1912. Self-resistance was not affected when the proton gradientdependent transporter gene IndJ and the ABC transporter gene IndW, both occurring in
the landomycin E biosynthetic gene cluster, were independently disrupted.
Heterologous expression of these genes, however, conferred resistance to landomycin
E, verifying their function as resistance genes [142, 143]. The intrinsic resistance of an
antibiotic producer is often due to the synergistic action of multiple gene products
[42]. This appears to be the case for HA self-resistance also as simultaneous disruption
of two putative HA resistance determinants, hygl9 and hyg21, resulted in a greater
decrease in resistance than when either of them was individually disrupted [140].
Sustained resistance of the HA non-producing Ahyg20 strain suggests that HA is not
essential for inducing the resistance genes.
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The Ahygl9 strain showed enhanced production of 5"-dihydrohygromycin A
(2) and a reduction in HA levels. Several examples are known where the final steps of
antibiotic biosynthesis are intricately balanced with efflux. In the case of nystatin
biosynthesis by S. noursei, disrupting the nysH and nysG genes for a putative type HI
ABC transporter resulted in accumulation of 10-deoxynystatin, a precursor of nystatin
lacking the hydroxyl at CIO [144]. Further, expression in the mutant strains of an
additional copy of nysL, which presumably encodes a monooxygenase for CIO
hydroxylation, increased nystatin production with a concomitant decrease in 10deoxynystatin. These observations indicated that the process of hydroxylation of the
precursor is balanced with efficient efflux of the nystatin formed. Similarly, in
landomycin A biosynthesis by S. cyanogenus, overexpression of the proton gradientdependent transporter gene lanJ or disruption of the regulatory gene lanK that
represses lanJ prevented completion of landomycin A biosynthesis and led to
premature efflux of a precursor landomycin D [145]. A dideacetylated precursor has
been suggested to be the true substrate for a type I ABC transporter present in
chromomycin A3 biosynthetic gene cluster in S. griseus subsp. griseus. It was
proposed that acetylation of the precursor occurs during transport by a membranebound acetyltransferase to form the final product, chromomycin A3 [146].

The results of hygl9 disruption indicate that compound 2 is the penultimate
product of the HA biosynthetic pathway, and that the conversion of 2 to HA by Hyg26
is the final step of HA biosynthesis, prior to efflux. The observed Hyg26 activity

supports this hypothesis. Since HA is the predominant product in the wild type, and as
altered antibiotic production is observed only in the Ahygl9 mutant, it can also be
hypothesized that the hygl9 gene product is responsible for selective and efficient
transport of HA under normal conditions. In the absence of hygl9, decreased
efficiency of HA efflux would have a negative feedback effect on the biosynthetic
pathway, resulting in lower HA yields and accumulation of 2. The presence of HA and
2 in the fermentation broth of Ahygl9 further implies the existence of an alternative
system for antibiotic efflux (FIGURE 37). This alternate transporter, which can
potentially be the /ryg2#-encoded ABC transporter, would have reduced selectivity
(exporting both HA and 2) relative to the process mediated by Hygl9. It will be
interesting to examine if the hyg28 gene is upregulated in the Ahygl9 strain compared
to the wild type.
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FIGURE 37. A working hypothesis for the roles of Hygl9 and Hyg28 in antibiotic
efflux. The proton gradient-dependent transporter, Hygl9, is the primary HA
transporter in the wild type. Efflux in the Ahygl9 strain is presumably brought about
by the ABC transporter, Hyg28, which is less selective for hygromycin A.

While compounds 2 and 5 exhibit better in vitro activity than HA, the
antibacterial activity is highest for HA (although the dataset is limited only to E. coli
assays). This suggests that the HA biosynthetic process has evolved to produce and
export HA as the major product because of some ecological advantage to S.
hygroscopicus in its environmental niche.
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The function of hyg26 as a gene encoding a short chain dehydrogenase /
reductase was already confirmed by gene disruption studies [40]. Most short chain
dehydrogenase enzymes are dimers or tetramers and typically do not need a divalent
metal ion for activity, unlike the classical metal-dependent 'medium chain' alcohol
dehydrogenases [147, 148]. Analyses of Hyg26 in the present study showed that it
occurs as a dimer and is metal ion-independent. The enzyme showed an absolute
preference for NAD(H) and did not utilize NADP(H) as coenzyme. The coenzymebinding site of short chain dehydrogenases preferring NAD(H) has an acidic residue
(Asp or Glu) that forms hydrogen bonds with the 2'- and 3'- hydroxyl groups of the
adenine ribose, whereas the binding site for NADP(H) has two basic residues (Arg or
Lys) that interact with the 2'- phosphate and the acidic residue is replaced by a
hydrophobic residue (Ala or Thr) [149, 150]. The specificity of Hyg26 for NAD(H) is
consistent with the presence of an Asp residue at position 38 in the putative
coenzyme-binding region in its sequence. The in vitro assays show that Hyg26 has
reversible activity, but the reductase reaction (reverse) appears to be more favored
than the dehydrogenase reaction (forward) under the given assay conditions. The high
Km values of Hyg26 for HA, 3, and 5 however indicate that the enzyme binds these
substrates very poorly. Such high intracellular concentrations of these compounds are
unlikely to exist under physiological conditions, considering the high efflux efficiency
of Hygl9. It is possible that, under physiological conditions, removal of intracellular
HA by its rapid export drives the Hyg26 reaction in the forward direction.
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A gene inactivation experiment targeting all the four putative resistance
determinants was also initiated to verify if HA self-resistance is conferred by any
genes that are not a part of the HA biosynthetic gene cluster, but could not be
accomplished due to technical difficulties. However, the present study has clearly
shown that the ABC transporter and the proton gradient dependent transporter are
individually dispensable for antibiotic efflux and self-resistance. On the other hand,
the final step of HA biosynthesis catalyzed by the short-chain dehydrogenase is
coupled with efficient efflux of HA by the proton gradient transporter (Hygl9), and in
the absence of Hygl9, there is accumulation of the C5"-reduced precursor.
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5. Conclusions and recommendations for future work

The work presented in this thesis describes the functional characterization of putative
self-resistance genes in the biosynthetic gene cluster of hygromycin A (HA). The
results have provided significant insights into the intrinsic resistance mechanisms of
the HA-producer, Streptomyces hygroscopicus NRRL 2388, and have also revealed
essential details about the biosynthesis of HA. The present data have also raised
important questions and opened up new opportunities for further studies on HA
biosynthesis and self-resistance.

Conclusion 1: The hyg21 gene in the HA biosynthetic gene cluster encodes an
ATP/GTP-dependent ^-phosphotransferase that modifies the C5"-OH of HA and
related compounds. Phosphorylation of HA abolishes its in vivo biological activity and
in vitro translation inhibition activity. Disruption of hyg21 also decreases HA
production significantly, but the self-resistance of S. hygroscopicus is not affected.

Future work: The function of hyg21 as a resistance gene can be verified by cloning
the gene into a HA-susceptible Streptomyces strain such as S. lividans and examining
it for acquired resistance to HA. Determining the HA resistance of the E. coli strain
expressing Hyg21 versus a control E. coli will also validate the role of this gene in HA
modification-mediated resistance. Genetic complementation of the Ahyg21 strain is
expected to restore HA production, thereby confirming that the decrease in antibiotic
yields is due to loss of hyg21 and not due to polar effects arising from gene disruption.
110

Further, growing the Ahyg21 strain in the presence of phosphorylated HA (HA-P) and
quantitating the antibiotic yields will reveal if HA-P has a regulatory effect on HA
biosynthesis.

Conclusion 2: The hyg6 gene encodes an O-methyltransferase that introduces the
methylene group in the C4-C5 methylenedioxy bridge of HA. Loss of the
methylenedioxy bridge reduces the antibacterial activity of HA. Disruption of the
second methyltransferase homolog, hyg29, does not affect antibiotic production profile
or self-resistance.

Future work: In vitro enzyme assays using recombinant Hyg6 and the proposed
structural intermediates in the aminocyclitol biosynthetic sequence as substrates will
determine the exact timing for O-methylation event in this pathway. Desmethylene
hygromycin A can serve as starting material for the synthesis of HA derivatives with
novel C4-C5 alkyl groups, thereby generating antibiotics with potentially improved
activity. Ligand docking studies can be carried out to analyze the differences in
binding of HA and related compounds to the 50S ribosomal subunit, and this
information can subsequently be used to design better ribosome-binding analogs. In
order to verify the proposed role of hyg29 as an rRNA methyltransferase gene, the
rRNA from the wild type and the Ahyg29 disruption strain can be examined for
differences in methylation. The predicted role of hyg29 can also be confirmed by in
vitro rRNA methylation assays using the recombinant enzyme. Drug binding assays
using ribosomes from the wild type and the Ahyg29 strain will also verify the
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existence of target site modification as a self-resistance mechanism in S.
hygroscopicus.

Conclusion 3: The hyg28 gene, which encodes a putative ATP binding cassette
transporter, is dispensable for HA biosynthesis and efflux. The hygl9 gene, which
encodes a putative proton gradient-dependent transporter, is essential for complete
progression through the biosynthetic pathway and for optimal levels of antibiotic
production. The dehydrogenation of 5"-dihydrohygromycin A by the NAD-dependent
Hyg26 is the last step of HA biosynthesis and is interlinked with efficient efflux of HA
by Hygl9. Self-resistance in S. hygroscopicus is a synergistic effect of more than one
resistance determinant.

Future work: The proposed roles of hygl9 and hyg28 gene products as resistance
determinants can be confirmed by expressing them in HA-sensitive strains and
determining their levels of resistance. It will be informative to compare the expression
levels of hyg28 in the wild type and the Ahygl9 mutant, because upregulation of
hyg28 in the Ahygl9 strain will identify it as the alternate transporter gene in the
absence of Hygl9. It will also be interesting to study the effects of disrupting both
hygl9 and hyg28 on antibiotic production and efflux. Complementing the Ahygl9
strain with the disrupted gene is expected to restore the antibiotic production profile,
which will verify that the accumulation of 5"-dihydrohygromycin A is an effect of
gene disruption, and that the efficient conversion of 5"-dihydrohygromycin A to HA
by the Hyg26 enzyme is dependent on the presence of Hygl9.
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